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ABSTRACT  
   
In an effort to begin validating the large number of discovered candidate 
biomarkers, proteomics is beginning to shift from shotgun proteomic experiments 
towards targeted proteomic approaches that provide solutions to automation and 
economic concerns. Such approaches to validate biomarkers necessitate the mass 
spectrometric analysis of hundreds to thousands of human samples. As this takes 
place, a serendipitous opportunity has become evident. By the virtue that as one 
narrows the focus towards "single" protein targets (instead of entire proteomes) 
using pan-antibody-based enrichment techniques, a discovery science has 
emerged, so to speak. This is due to the largely unknown context in which 
"single" proteins exist in blood (i.e. polymorphisms, transcript variants, and 
posttranslational modifications) and hence, targeted proteomics has applications 
for established biomarkers. Furthermore, besides protein heterogeneity accounting 
for interferences with conventional immunometric platforms, it is becoming 
evident that this formerly hidden dimension of structural information also 
contains rich-pathobiological information. Consequently, targeted proteomics 
studies that aim to ascertain a protein's genuine presentation within disease-
stratified populations and serve as a stepping-stone within a biomarker 
translational pipeline are of clinical interest.  
Roughly 128 million Americans are pre-diabetic, diabetic, and/or have kidney 
disease and public and private spending for treating these diseases is in the 
hundreds of billions of dollars. In an effort to create new solutions for the early 
detection and management of these conditions, described herein is the design, 
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development, and translation of mass spectrometric immunoassays targeted 
towards diabetes and kidney disease. Population proteomics experiments were 
performed for the following clinically relevant proteins: insulin, C-peptide, 
RANTES, and parathyroid hormone. At least thirty-eight protein isoforms were 
detected. Besides the numerous disease correlations confronted within the 
disease-stratified cohorts, certain isoforms also appeared to be causally related to 
the underlying pathophysiology and/or have therapeutic implications. Technical 
advancements include multiplexed isoform quantification as well a "dual-
extraction" methodology for eliminating non-specific proteins while 
simultaneously validating isoforms. Industrial efforts towards widespread clinical 
adoption are also described. Consequently, this work lays a foundation for the 
translation of mass spectrometric immunoassays into the clinical arena and 
simultaneously presents the most recent advancements concerning the mass 
spectrometric immunoassay approach. 
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Chapter 1 
INTRODUCTION 
THE DAWN OF PROTEOMICS 
During the 1980’s peak in biological reductionist research, which was centered on 
the philosophy that one should begin by correlating an observed phenotype 
followed by an investigation of the genes and proteins responsible, i.e. forward 
genetics, a would be emerging field, proteomics, was being formulated out of a 
complimentary field: protein chemistry. Underneath the umbrella of protein 
chemistry, efforts geared towards the development of more sensitive and reliable 
sequencing technologies for protein characterization were underway.  One such 
method, despite being slow and having poor sensitivity relative to modern 
methods, Edman sequencing of two-dimensional gel electrophoretically separated 
(2DE) proteins provided crucial information regarding the N-terminal portion of 
an intact protein or tryptic fragment, thus providing link between understanding 
the activity of a protein and it’s corresponding gene. From derived sequence 
information, one could now synthesize degenerate oligonucleotide primers and 
the respective gene could be cloned using PCR (1). These technological 
breakthroughs fueled the growth and development of evermore detailed and 
sophisticated sequence databases. Eventually a collective paradigm shift began to 
take root, a reverse approach, wherein one studies and/or manipulates genes and 
proteins a priori, followed by phenotype observation, i.e. bottom up. High-
resolution 2DE coupled to computer software programs built for the interpretation 
of resulting large quantities quantitative protein profile data provided researchers 
   2
with the tools necessary begin this journey (1980s) (2, 3).  Indeed, ideas such 
building protein databases from resulting 2DE protein profiles began to emerge, 
as was the case with the human protein index (4).  It was within this framework of 
large-scale discovery science that technologies such as 2DE would pave the road 
for the development of a field of research that would eventually yield the 
discovery of thousands (if not tens of thousands) of putative disease-correlated 
biomarkers. 
 
MASS SPECTROMETRIC DETECTION OF LARGE BIOMOLECULES 
COME OF AGE 
The realization of proteomics would not have been possible without the advent of 
mass spectrometry (MS) towards protein characterization via the development of 
matrix-assisted laser desorption ionization (MALDI) and electrospray ionization 
(ESI) in the late 1980’s (3, 5, 6). MS could now allow protein chemists the 
possibility to identify and examine the proteins resolvable by 2DE. This 
dramatically increased the possibilities of large-scale protein studies where the 
intent is to not only separate and quantify complex protein mixtures, but to also 
provide unambiguous protein identification per resolvable 2DE spot. The strength 
of MS lies in its ability to detect the mass-to-charge (m/z) of an analyte, and as 
such, the analyte must become ionized for it to be detected. Before ESI and 
MALDI, MS instruments failed to successfully volatize proteins and/or involved 
excessive fragmentation (3). The 2002 Nobel Prize winner John Fenn described it 
as “it’s like making elephant’s fly”. Regarding the mass analyzer component of 
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typical MS scheme, time-of-flight (TOF) for MALDI and triple-quadruple 
MS/MS or ion-trap for ESI proved to be powerful instruments in this emerging 
field of discovery proteomics. Due to issues including the lack of specificity for 
typical proteomic experiments, the overlapping nature of eukaryotic proteins in 
general over a typical m/z window when using MALDI, and intrinsic instrument 
limitations wherein high-resolution data is only achievable for low m/z, the use of 
trypsin was employed to offer a means for a high-degree of protein identification 
due to unique peptide masses, aka “fingerprints.” The paradigm of digest first 
then analyze (i.e. bottom-up proteomics) would take deep root within the 
collective mindset of the proteomics field. While effective for certain 
applications, the pervasive use of trypsin would later become questionable due to 
the unknown landscape of intact proteins. 
Besides being labor intensive, expensive, and the inherent lack of automation, 
the discovery of a high degree of co-migrating proteins in a typical 2DE analysis 
via MS detection fueled the desire for a new separation technology to emerge for 
large-scale protein studies (3, 7). Furthermore, limitations in proteome coverage 
where proteins have extreme pI values (isoelectric point), and/or molecular 
weights, as well as the sub-standard level of membrane protein detection, 
supported the idea that 2DE might be fundamentally restricted (8). Thus, the 
groundwork was laid for gel-independent methodologies to take the stage for 
proteomic studies.  
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ENTER DISCOVERY PROTEOMICS 
In 1994, the word proteome was coined and was defined as the protein 
complement of the genome (9). In 2003, Patterson (3) defined proteomics as 
“…the systematic study of the many and diverse properties of proteins in a 
parallel manner with the aim of providing detailed descriptions of the structure, 
function, and control of biological systems in health and disease.” As a collective 
group, proteomics up until this point in time was primarily focused on the 
discovery of diagnostic and prognostic biomarkers and novel drug targets. In the 
mid nineties and up until modern times, LC-MS/MS (liquid chromatography 
tandem mass spectrometry) coupled with sequence database searches of digested 
(e.g. Trypsin) complex samples emerged as the mainstream approach for 
discovery proteomic studies, aka shotgun proteomics (3). Such methods employ 
one or more dimensions of separation before MS detection, which enables a more 
effective protein analysis (e.g. an improved qualitative dynamic range).  One such 
method called multidimensional protein identification technology (aka MudPIT) 
utilizes a first dimension of separation via strong cation exchange 
chromatography wherein discrete additions of salt concentration are added to the 
column followed by a C18 reverse phase (RP) chromatography separation step. 
Eluted peptides are then detected via tandem MS (commonly via an ion-trap) (8). 
Such technologies are powerful in that a single experiment may yield thousands 
of identifiable proteins. Despite shotgun proteomic technologies revealing 
thousands (possibly hundreds of thousands) of candidate biomarkers from the 
human proteome, validation of such proteomic data (i.e. targeted proteomics) 
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requires the use of hundreds to thousands of samples. A refined, yet 
complimentary, methodology to conventional discovery proteomic techniques is 
required as a single “discovery” experiment can take weeks to analyze a relatively 
small sample set (n < 10) (10). Indeed, Parker et al. states “only a small number of 
the reported ‘candidate’ biomarkers have been qualified or verified, and even 
fewer have been validated, which requires measuring the proposed biomarker in 
even larger groups of patients” (10). Astonishingly, only 7 markers were FDA 
approved between 2003 and 2008 (11), stressing the necessity for translational 
proteomic technologies to enter into mainstream workflows. 
TARGETED PROTEOMICS  
Automation of sample processing, time and cost per analysis, and finally robust 
data processing methods are some of the motivating forces driving targeted 
proteomics and the respective competing methods (as outlined below) towards the 
realization of 1000+ sample cohort studies (10). Furthermore, due to the reality 
that only a few abundant proteins comprise upwards of 90% of the entire plasma-
protein mass (12), plasma proteins exist within a dynamic range of 1010 (13), and 
that MS instruments suffer from suppression effects when multiple analytes are in 
the ion-source at the same time (10), antibody-based enrichment techniques have 
taken the center stage in targeted proteomics when the intent is to quantify the 
mid-range to low abundant proteins (i.e. the target is already known, as opposed 
to discovery proteomics). Additionally, despite enzyme-linked immunosorbent 
assays (ELISA) still holding the throne for conventional biomarker quantification, 
assay development costs tend to be extremely high (14), multiplexing potential is 
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not as great as with proteomic approaches, and substantial assay interferences 
from non-specific proteins and/or non-bioactive protein variants are becoming 
well-acknowledged as pervasive (15-18). Thus the need for a biomarker 
translational pipeline exists if the large quantity of candidate biomarkers are to be 
translated into the real world. Two modern and well-acknowledged targeted 
proteomic methods include SISCAPA (Stable Isotope Standards and Capture by 
Anti-Peptide Antibodies) and MSIA (Mass Spectrometric Immunoassay). 
The SISCAPA workflow starts with sample digest (i.e. an entire plasma 
sample is denatured and digested at a ratio of 1:80 trypsin/plasma mass), followed 
by addition of heavy labeled internal standards, enrichment of peptides using anti-
peptide antibodies immobilized to a bead-based support which are specific for a 
known tryptic sequence, and concludes with peptide elution followed by detection 
via single reaction monitoring (SRM) or multiple reaction monitoring (MRM) 
LC-MS/MS (19).  With it’s recent debut in 2003, SISCAPA has “taken off”, so to 
speak. An August 2011 Google Scholar search of “SISCAPA” yielded 333 hits, 
indicating a very strong presence of this emerging proteomics technology. In 
2010, Whiteaker et al. demonstrated an automated iteration of SISCAPA that was 
also multiplexed wherein nine protein targets (via respective surrogate tryptic 
fragments) were quantified at relatively low plasma concentrations (~nM) and 
with adequate precision (a median coefficient of variation of 12.5% was reported) 
(14). Despite the early success of SISCAPA, there are a few notable deficiencies 
that need to be addressed. Due to varying tryptic digest efficiencies, which are 
protein specific, a significant amount of variance is introduced into an assays 
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performance (not to mention the excessive amount of trypsin required per 
analysis). The assay is also not quite yet suitable for large-scale studies due to 
throughput limitations. Sample studies comprised of small cohorts typically take 
days, although advancements in higher capillary flow-rates could accelerate 
sample processing (10). Furthermore, a large reservoir of clinically relevant 
proteins exist at sub-nM concentrations in plasma (e.g. Insulin exists in the low 
pM range (20)), and thus, SISCAPA as it currently stands, does not provide 
adequate performance to quantify proteins of interest within an essential clinical 
range of human biomarkers. Perhaps SISCAPA’s most questionable attribute is 
found within the first step of the protocol: sample digestion prior to peptide 
capture.  
Recent studies have shown that there appears to be a pervasive backdrop of 
protein diversity within plasma comprised of structurally alike but functionally 
distinct proteins (18, 21-24), and as such, this large pool of putative clinical data 
is forfeited when a sample is digested prior to peptide or protein capture for MS 
detection (variants become merged into a single signal). Thus, targeted proteomic 
technologies that can provide the clinical metrics necessary for widespread 
adoption including pM and lower sensitivity, CVs ≤ 10%, multiplex mode, 
automation, are cost efficient, and can detect potential and known protein 
heterogeneity distinct from one another may provide target proteomics the 
approach necessary for wide-spread adoption into clinical diagnostics.  
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Notwithstanding, such a technology may open up a new and unexpected 
progression yielding the unification of discovery and targeted proteomics into a 
single scientific field. 
MSIA technology debuted in 1995 (25) and could be considered ahead of it’s 
time considering the recent (mid 00’s) large-scale movement within proteomics 
towards the validation of candidate biomarkers using antibody-based enrichment 
techniques. Although the method was originally presented using MALDI-TOF 
MS detection, the method can be translated to most MS instruments (26, 27). 
Conceptually, MSIA can be considered a micro-affinity column whereby analytes 
from complex protein mixtures (e.g. serum, plasma, urine, etc.) are rinsed 
repeatedly through the column and retained due to antibody-protein coulombic 
forces, Van der Waals forces, hydrogen bonding, and hydrophobic interactions. 
Micro-columns are created using commercially available wide-bore P-200 
pipettor tips fitted with a solid support frit at the base at the barrel (chemically 
treated with 15-kDa molecular mass carboxylated dextran) (28). The use of 
pipette tips allows seamless integration into modern robotic workstations, thus 
engendering high-throughput capabilities. The frits are subsequently treated with 
varying customized antibody immobilization chemistries, which allow for 
optimized singleplex or multiplex MSIA functionality (i.e. multiple covalently 
linked antibodies per tip). Assuming the antibody binds to the tip with an average 
orientation supportive of antigen binding (which can be modified using alternative 
binding chemistries), and practical thermodynamic considerations are 
acknowledged including the antibody’s dissociation constant (Kd), the total 
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amount of concentration of antigen (free and bound), the volume of the sample, 
the total amount of antibody (free and bound), and finally the total amount of 
theoretically bound antigen for MS analysis (i.e. it must be within the detection 
range of the mass spectrometer) (29), the next stage of assay development may 
commence.  
Strategic application of buffers, salts, and detergents to biological samples 
prior to antigen extraction enhances MSIA performance via improved antigen-
antibody binding, the release of antigen from pre-existing biological protein-
complexes, and minimal non-specific binding the MSIA pipette tip (16, 30). 
Furthermore, the use of a chemically modified protein or heavy isotope labeled 
peptide/protein may be introduced into the sample to serve as an internal standard 
for MS quantification. After antigen extraction, MSIA tips are rinsed using 
various combinations of buffers and detergents that simultaneously respect the 
antigen-antibody complex and remove non-specifically bound species. Prior to 
MS detection, antigen-antibody complexes are disrupted typically by the use of an 
acidic solution (e.g. sinapic matrix for MALDI or formic acid for ESI). Finally, 
proteins are qualitatively and/or quantitatively detected as intact proteins, or 
alternatively, as proteotypic fragments resulting from a post-elution enzymatic 
digestion via MS (i.e. a high-degree of protein variant information is still 
embedded within the sample). An additional level of specificity can also be 
achieved, although is not always mandatory, via the use of tandem MS. As one 
might expect, the MSIA technology has matured in the past 2 decades and has 
displayed an aptitude to rival conventional ELISA-based technologies (as well as 
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SISCAPA) via the successful execution of high-throughput cohort studies 
comprised of patient populations in the thousands (31), detection of analytes in 
volumes containing sub-fmol quantities of analyte (see chapter 4) (32), and 
perhaps most interestingly, simultaneous quantification of both native and post-
transnationally modified proteins (see chapter 5) (26, 29). 
 
THE NEED FOR FULL-LENGTH PROTEIN POPULATION STUDIES  
Despite the human genome being comprised of an estimated 22,333 genes (33), 
the human body likely encompasses millions of gene products, which arise out of 
genetic transcript variants, polymorphisms, and posttranslational modifications. 
This resulting protein diversity paints a very different picture from what 
traditional discovery proteomics might lead one to believe.  This can be observed 
by recognizing a reoccurring theme in proteomics wherein genetic products tend 
to be correlated to a single native-protein or tryptic “fingerprint.” Regardless, 
within the human body there is an underlying sea of protein diversity that flows 
from the interior of human cells into the blood stream, and is even further 
diversified from the host of chemical reactions that occur within blood. As such, 
this provides at least two significant implications for diagnostic technologies: 1) 
there is a high probability for negative assay interferences arising from 
interactions with modified forms of proteins that have altered functionality, 
ultimately compromising the efficacy of an assay (15) and 2) the possibility of 
acquiring determinant data linked to specific disease via technologies that can 
detect protein isoforms (21).  Mass spectrometers empower the pursuit of this new 
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form of data, as they can, with ease, discriminate between highly similar forms of 
proteins from their unique parent m/z and/or resulting daughter-ions from tandem 
MS. Ironically, the past two decades of proteomics has largely ignored this 
opportunity. By approaching bloodborne protein characterization from a “we 
don’t know what we don’t know” paradigm in tandem with mass spectrometric 
analysis, researchers have an opportunity to potentially redefine the underlying 
assumptions surrounding protein-based diagnostics. As such, studies that aim to 
explore the underlying depth of bloodborne protein diversity within human 
disease-stratified populations may simultaneously enable a high-throughput 
pipeline for candidate biomarker validation (e.g. RANTES), and may also provide 
the means for classical biomarkers, such as Insulin, C-peptide and Parathyroid 
Hormone, to be reevaluated and potentially redefined within this exciting new 
framework of population proteomics.  Proteomics, as with most scientific fields 
of research, exemplifies the characteristic of an ever-evolving field of thought, 
and despite the slow translation of candidate biomarkers and the under-
appreciated reality of protein diversity, proteomics may be experiencing a 
renaissance as it ascends into the real world of clinical diagnostics. 
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Chapter 2 
MASS SPECTROMETRIC IMMUNOASSAYS FOR DIABETES 
At the turn of the century, it was estimated that 2.8% of the world population had 
diabetes (accounting for 171 million individuals) (34). According to the Center 
for Disease Control and Prevention (CDC), it was estimated that 26 million 
Americans had diabetes and 79 million Americans had pre-diabetes in the year 
2010. Even more striking, 1 in 3 individuals in United States that were born in the 
year 2000 are estimated to develop diabetes within their lifetimes, indicating the 
prevalence the disease is expected to increase profoundly (35). Consequently, the 
burden on the American economy is weighty, with a conservative estimate 
placing total costs incurred in 2002 alone at 132 billion dollars (36). This 
worldwide epidemic has motivated extensive research into the biological 
underpinnings of this devastating disease.  
Diabetes, a multifaceted metabolic disease, results primarily from defects in 
pancreatic β-cell insulin secretion and/or defects in insulin action on target tissues. 
Diabetes is currently monitored and diagnosed primarily by the downstream 
physiological aftermath of resulting hyperglycemia found in blood. Long-term 
hyperglycemia has been shown to result in the damage, dysfunction, and failure of 
organs including nerves, eyes, kidneys, heart, and blood vessels (37, 38). Diabetes 
is currently classified within two etiopathogenetic categories: type 1 diabetes 
(T1D) and type 2 diabetes (T2D). T1D simply involves a total insulin secretion 
deficiency via autoimmune processes resulting on the destruction of β-cells. T2D 
is a much broader disease encompassing hosts of distinct molecular pathways, but 
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in its most broad sense, causes insulin resistance and/or inadequate insulin 
secretory response. As such, the resulting inaction of insulin towards carbohydrate 
metabolism results in above average basal glucose levels in diabetics (defined by 
a fasting plasma glucose (FPG) ≥ 126 mg/dL or via an oral glucose tolerance test 
≥ 200 mg/dL). Over time, this results in the non-enzymatic glycation of proteins 
such is the case with hemoglobin A1C, a clinically used biomarker (≥ 6.5% total 
hemoglobin A1C is indicative of diabetes). This marker is interesting in that it 
provides a longitudinal assessment of a patient’s history via the extended half-life 
of A1C, with A1C levels representing average blood glucose levels over a 2-3 
month period (37, 39). Although current gold standard assays (e.g. glucose and 
A1C) are indisputably helpful in the broad classification of this disease, new 
diagnostic tests and panels have the potential to dramatically improve the 
diagnosis and treatment on an individual level. 
In addition to monitoring the time-sensitive posttranslationally modified 
protein marker A1C, investigating more in-depth biomarker panels that address 
native forms and variant forms within the context of diabetes via mass 
spectrometric immunoassays may enable a more precise diagnosis of diabetes 
within specific groups of individuals. As a consequence, this may yield the 
necessary findings for the development of next-generation antidiabetes 
medications. Similarly, new insights into the pathobiology of diabetes and related 
comorbidities (e.g. coronary artery disease) via detection of oxidized proteins 
induced by systemic oxidative stress and/or protein truncation produced by 
enzymes involved in disrupted hormone pathways (40) have the opportunity to 
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expand the definition and classification of diabetes and related comorbidities. 
Consequently, such “isoform-aware” assays have the potential to provide a never-
before-seen level of detail within an individual and might support the realization 
of personalized medicine for the treatment and management of diabetes and 
related comorbidities. Within this framework, population proteomics studies were 
undertaken to investigate the classical biomarkers C-peptide and insulin and the 
more contemporary, candidate biomarker, RANTES (i.e., Regulated on 
Activation, Normal T cell Expressed and Secreted). 
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Chapter 3 
C-PEPTIDE MICROHETEROGENEITY IN TYPE 2 DIABETES 
POPULATIONS 
In response to elevated blood glucose levels within the beta cells of the pancreatic 
islets of Langerhans, preproinsulin is produced in the endoplasmic reticulum and 
is cleaved by microsomal enzymes to generate proinsulin. Proinsulin is 
subsequently transported to the Golgi apparatus and packaged into clathrin-coated 
secretory granules, where it is processed by a cascade of proconvertases and 
carboxypeptidases, resulting in the portal circulation of equimolar amounts of C-
peptide and insulin (41-43). The reported half-life of C-peptide in plasma is 
between 20-30 minutes and its concentration is 3-5 times that of insulin (42, 44-
46). 
Conventionally, C-peptide functions as a mediator/connector in the protein 
folding of the proinsulin precursor molecule to facilitate two disulfide bridges 
between the α- and β-chains of the insulin molecule. Excluding this well-
established role in the insulin biosynthesis pathway, the physiological functions of 
C-peptide have remained largely undefined. Recently, however, C-peptide has 
been shown to have alleviating physiological effects towards diabetes. Diabetic 
rats with pharmacological doses of C-peptide demonstrated a restoration toward 
normal of the diabetes-induced decrease in cellular sodium-potassium adenosine 
triphosphatase (ATPase) activity and impaired nerve conduction, and a decrease 
in the diabetes-induced increase in vascular permeability and blood flow (47). 
Moreover, structural studies indicate the C-terminal pentapeptide segment (27-31 
   16 
residues, particularly Glu27) as the site of receptor-ligand binding which is 
thought to be responsible for increasing intracellular Ca2+ concentrations, 
stimulation of MAP kinase signaling pathways, and the stimulation of Na+,K+-
ATPase and endothelial eNOS. However, it is possible that there are other 
signaling pathways involved (42, 48-51). 
In clinical application, C-peptide is a useful indicator for differentiating 
between type 1 and type 2 diabetes (42, 44, 52-54). Low fasting levels of C-
peptide are used in combination with other biomarkers to classify diabetics as 
having idiopathic type 1 diabetes of nonautoimmune or autoimmune origin. C-
peptide concentrations are generally measured using immuno-based assays such 
as enzyme-linked immunosorbent assays (55) and radioimmunoassay (56), or 
fluorescence (57, 58). However, a recent study investigating the inter-assay and 
inter-laboratory reproducibility of these industry-standard assays has reached the 
conclusions that results generated by different methods and laboratories do not 
always agree, and that calibrating C-peptide measurement to a reference method 
can increase comparability between laboratories (57). The reference method 
indicated in this recent study is isotope-dilution mass spectrometry (ID-MS), 
which is a natural extension of a significant body of work using mass 
spectrometry for the accurate quantification of C-peptide (59-65). In particular, 
two methodologies, – either 2D-LC/MS operating in select ion monitoring mode 
(59), or LC-MS/MS operating in a multiple reaction monitoring mode (60) – have 
demonstrated excellent analytical metrics (e.g., in accuracy (94.6 – 104.1% (60)), 
precision (CV < 1.5% (59); CV < 4% (60)), LOD 10 pM (60) and LOQ ~ 50 pM 
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(59, 60)) for the quantification of intact C-peptide. Accordingly, these approaches 
are likely to become “gold standard” assays for C-peptide (57, 63). 
 One caveat of the ID-MS approaches (as they are described, e.g., (59, 60) 
without full-scan data), as well as the conventional immunometric assays, is the 
inability to differentiate between wild-type and variant forms of C-peptide that 
might be encountered in plasma. Formally, the consideration of such 
microheterogeneity may help to explain measurement discrepancies found 
between ID-MS and conventional assays. Alternatively, from a biological 
perspective the study of microheterogeneity is important when considering that 
genetic and posttranslational variants of proteins contain additional information 
regarding the personal makeup of an individual, which in turn may have 
significant implications towards personalized medicine. For example, inactivation 
of peptide hormones by N-terminal dipeptide truncation via Dipeptidyl Peptidase 
IV (DPP-IV), such as glucagon-like peptide-1 (GLP-1), result in multiple 
endogenous isoforms which can begin to describe an individual’s state of 
enzymatic activity (e.g. DPP-IV activity) and peptide signaling activity (e.g. the 
relative abundance of the agonist form of GLP-1) (66).  In addition, in 
acknowledging that increased activity levels of protein regulatory enzymes have 
been in many cases disease correlated, such as with T2D and DPP-IV (67), it is 
essential to take an in-depth look at the breadth of protein microheterogeneity. 
Thus, future studies stand to benefit from a more complete survey of 
qualitatively different variants of C-peptide as they exist in healthy and diseased 
populations. To this end, this report focuses on the use of mass spectrometric 
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immunoassay (MSIA) (25) to map structural differences in C-peptide found in 
healthy and type 2 diabetes (T2D) populations.  
 
EXPERIMENTAL 
STUDY SUBJECTS, SAMPLE COLLECTION AND PREPARATION 
CDI (1,1'-Carbonyldiimidazole)-activated affinity pipette tips were prepared and 
derivatized with mouse anti-human C-peptide antibody (AbD Serotec), as 
previously described for other antibodies (23). For the development of the assay, 
healthy human female plasma was purchased from ProMedDx (Norton, MA). 
Ninety six additional human plasma samples (equaling 48 healthy individuals, 12 
insulin dependent type 2 diabetics, and 36 non-insulin dependent type 2 diabetics) 
were purchased from ProMedDx. Five hundred microliters of human plasma  was 
pre-treated with 250 µL of a solution containing: 4.5 % Tween 20, 150mM Octyl-
β-glucopyranoside, 1.5M Ammonium Acetate, and Concentrated PBS (0.67M 
sodium phosphate, 1M sodium chloride), for a total analytical volume of 0.75 mL.  
 
PLASMA MASS SPECTROMETRIC IMMUNOASSAYS 
C-peptide was extracted with the aid of a Beckman Multimek 96 pipetting robot 
by repeatedly (250 repetitions) drawing and expelling (back into the analytical 
volume) 125 µL aliquots of the analytical volume through an anti-C-peptide 
affinity pipette. After extraction, the pipettes were rinsed using PBS (0.1M 
sodium phosphate, 0.15M sodium chloride, pH 7.2), HBS-P (0.01M HEPES, 
0.15M NaCl, 0.05% v/v Surfactant P20, pH 7.4), H2O, 100mM 
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Tris(hydroxymethyl)aminomethane hydrochloride (pH 4.6), and H2O (in this 
order, each rinse = 10 repetitions of 150 µL), after which C-peptide was eluted 
and prepared for MALDI-TOF MS by drawing 4 µL of MALDI matrix solution 
(saturated aqueous solution of α-cyano-4-hydroxycinnamic acid, in 33% (v/v) 
acetonitrile, 0.45% (v/v) trifluoroacetic acid, TFA) into the pipette and depositing 
onto a MALDI target. 
 
MASS SPECTROMETRY 
MALDI-TOF MS was performed using a Bruker Ultraflex MALDI-TOF 
instrument operating in the negative ion, delayed-extraction mode; reflector 
engaged with ‘ion source 1’ at 20.00 kV, ‘ion source 2’ at 17.45 kV, lens at 7.50 
kV, ‘reflector’ at 21.00 kV, ‘reflector 2’ at 10.95, 60 ns delayed extraction, 
deflection signal suppression up to m/z 1500, and 2 GS/s sample rate. Two 
hundred laser-shots were signal averaged for each mass spectrum.  Single stage 
MALDI-TOF mass spectra were externally calibrated with a mixture of 6 peptides 
supplied by Bruker (Cat. No. 208241) ranging in monoisotopic m/z from 1044.53 
(Angiotensin II [M-H]-) to 3145.46 (Somatostatin [M-H]-) 
 
DATA ANALYSIS 
Individual mass spectra were baseline subtracted and smoothed prior to peak 
integration.  Peaks representing the five most abundant C-peptide and C-peptide-
variant isotopes were integrated and tabulated in a spreadsheet for determination 
of percent relative abundances. 
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TANDEM MASS SPECTROMETRY 
LIFT-TOF/TOF mass spectra of C-peptide were acquired on a Bruker Ultraflex 
MALDI-TOF/TOF instrument in positive ion mode using sinapic acid as a matrix.  
Precursor ions were selected within a 30 Da mass window.  The LIFT-TOF/TOF 
instrument control method was calibrated according to the instrument 
manufacturer’s protocol and was run without CID gas. 
 
RESULTS AND DISCUSSION 
Figure 1 shows a MSIA spectrum qualitatively representative of those obtained 
for the individuals investigated in this study. In addition to intact C-peptide 
(observed monoisotopic m/z 3017.50), signals registering at m/z 2888.49, 
2817.45, and 2688.41 (labeled I, II and III, respectively) were observed at varying 
relative intensity in many but not all samples throughout both the healthy and 
T2D cohorts (n = 48 each).  The sequence of human C-peptide is:  
H2N—EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ—COOH 
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Figure 1: C-peptide MSIA spectrum qualitatively representative of the 
subjects in this study. The mass spectrum contains the intact form of C-peptide 
as well as C-peptide (2-31) (calc. monoisotopic m/z 2888.47), C-peptide (3-31) 
(calc. monoisotopic m/z 2817.44), and C-peptide(4-31) (calc. monoisotopic m/z 
2688.39).  These N-terminally truncated variants had signals registering at m/z = 
2888.49, 2817.45, and 2688.41 (labeled as I, II and III, respectively). The loss of 
ammonia from the N-terminus is observed on all native and variant forms and is 
frequently observed under reflector-TOF-MS conditions. 
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Two major considerations arise from protein surveys such as this one that are 
conducted across human populations.  First, the concept of populational frequency 
addresses the question of the number of samples (out of the total) in which a 
particular protein variant was observed with signal to noise ratio greater than 
three: Out of the forty eight type 2 diabetics, isoform I was observed in 1 subject, 
isoform II in 44 subjects, and isoform III in 1 subject.  In the healthy cohort, 
isoform I was observed in 9 subjects, isoform II in 43 subjects, and isoform III 
was not observed. 
Second, the relative percent abundance (RPA) of each unique variant may be 
obtained (without the use of an internal standard) by integrating all mass spectral 
peak areas corresponding to variant forms of the target protein, then dividing the 
peak area of each variant form by the summed areas of all forms and multiplying 
by one hundred.  The use of affinity capture ensures that spurious peaks unrelated 
to the target protein do not arise in the mass range of interest.  Using this form of 
relative quantification, the RPA for C-peptide variant II was evaluated with 
respect to the presence of T2D by grouping data from individuals into their 
respective cohorts. Table 1 presents the average RPA with standard deviation as 
well as RPA range of intact C-peptide and variant II within the T2D and healthy 
cohorts. (Variants I and III were not tabulated in analogous manner because they 
were infrequently detected throughout both cohorts.) 
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Table 1: Average relative percent abundance (RPA) and RPA range of C-peptide (1-31) and C-
peptide (3-31) for the T2D and healthy cohorts. 
   
RPA is obtained following peak area integration by dividing each individual peak area by the sum of all 
peak areas representing C-peptide and multiplying by 100. RPA range provides the low and high values 
observed for each variant in the two 48 sample cohorts described here. 
 
a)  The population distribution of C-peptide(3-31) for the RPA ranges of healthy and diabetic 
individuals are given in Figure 2. 
b)  Statistically significant from the healthy cohort at p < 0.01 
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Interestingly, the relative contribution of variant II was found to be comparatively 
different between the T2D and healthy cohorts. Figure 2 shows histograms 
comparing the frequency of occurrence between the two cohorts for the RPA of 
variant II. A broad distribution averaging 10% RPA (average of all individuals in 
the cohort) was observed for the T2D cohort, as compared to a narrow distribution 
averaging 5% RPA observed for the healthy cohort. Taking these differing 
variances into account, the average RPA for variant II in the T2D cohort was 
found by t-test to be significantly different from the healthy cohort at p < 0.01. 
To verify repeatability of the assay, plasma from a single donor was divided 
into 96 aliquots and analyzed as described above. The average RPA value for 
unmodified C-peptide was 93% ± 1.0% SD and the average RPA for variant II 
was 7.4% ± 1.0% SD. 
Given accurate mass determination (within 10 ppm), variants I, II and III can 
be can be tentatively identified as truncated forms of C-peptide respectively 
lacking one, two or three N-terminal amino acids (i.e., C-peptide (2-31), C-
peptide (3-31) and C-peptide (4-31)). Because of its observed greater contribution 
in the diabetic population, tandem mass spectrometry was used to confirm the 
identity of variant II via partial sequencing. For reference, Figure 3A shows a 
MALDI-TOF/TOF-MS spectrum obtained from intact C-peptide (positive mode 
m/z = 3019.50). Signals are observed to align predominantly with y-ions (with 
~0.2 Da mass accuracy) yielding a fragmentation signature for intact C-peptide. 
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Figure 3B shows a tandem mass spectrum obtained for variant II aligned to the 
sequence of C-peptide (3-31). Although of lower signal intensity, the y-ion 
fragmentation series registers the same pattern and mass as the intact C-peptide 
series (note the three overlaid enlarged glycine registers) which is expected for N-
terminally truncated peptide forms. Notably, the signal for the b-ion of C-
peptide(1-31) terminating at Q22 is observed at m/z 2093.1, but the b-ion of the 
putatively truncated C-peptide terminating at the same glutamine residue is 
shifted in mass by -200.2 Da, which corresponds to the mass difference associated 
with the loss of the N-terminal Glu-Ala dipeptide.  
Figure 2: Variant II frequencies. Expanding upon the last row of Table 1, these 
histograms provide the frequency of occurrence within the Healthy and T2D 
populations for the relative percent abundance of variant II. A broad distribution 
averaging 10% RPA (average of all individuals in the cohort) was observed for 
the T2D cohort, as compared to a narrow distribution averaging 5% observed for 
the healthy cohort. 
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Together, the affinity extraction, mass mapping, and MS/MS data firmly support 
the conclusion that variant II is C-peptide(3-31).  
Previous to this study, another C-peptide variant – in the form of C-peptide (1-
26) – had been reported in the literature. This variant form was first discovered in 
Figure 3: MS/MS of C-peptide (1-31) and C-peptide (3-31).  (A) MALDI-
TOF/TOF-MS spectrum of intact C-peptide (positive mode m/z = 3019.50; calc. 
monoisotopic m/z = 3019.52). (B) MALDI-TOF/TOF-MS spectrum of variant II 
aligned to the sequence of C-peptide (3-31). The y-ion fragmentation series 
registers as the same pattern and mass as the intact series (note the three overlaid 
blue glycine registers), which is expected for N-terminally truncated peptide 
forms. The signal for the b-ion of C-peptide (1-31) terminating at Q22 is observed 
at m/z 2093.1, but the b-ion of the putatively truncated C-peptide terminating at 
the same glutamine residue is shifted in mass by -200.2 Da, which corresponds to 
the mass difference associated with the loss of the N-terminal Glu-Ala dipeptide. 
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rats but was later found to exist at very low relative abundance in humans.  
Furthermore, it was not observed to increase in individuals with T2D or 
insulinoma (68, 69). To our knowledge, however, N-terminally truncated forms 
have yet to be reported or studied. The consequences and utility of the truncated 
variants are thus not understood, but are intriguing; in particular, the observation 
of elevated levels of C-peptide (3-31) in the diabetic population. Structural and 
biophysical characterization of dipeptidyl peptidase IV (DPP-IV; EC 3.4.14.5) 
(70), a multifunctional type II transmembrane serine peptidase, reveals a preferred 
enzyme specificity of Xaa-Pro or Xaa-Ala from the amino termini of peptide 
hormones. Moreover, DPP-IV is a critical enzyme in regulating physiological 
glucose homeostasis via N-terminal cleavage of peptide hormones such as 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) (66). As such, control of DPP-IV activity via drug formulations 
is a major focus of new T2D drug development (71-73). Observation of C-peptide 
(3-31) is thus consistent with DPP-IV cleavage at the N-terminal GluAla- of C-
peptide, and the elevated levels observed in the diabetic population may be 
explained by abnormal DPP-IV activity in the diabetic population. If C-peptide is 
indeed an in vivo substrate for DPP-IV, these results are in alignment with 
previous work that showed an increase in DPP-IV activity in T2D individuals 
with moderate to severe hyperglycaemia relative to newly diagnosed diabetics, 
impaired glucose tolerance subjects, and normal glucose tolerance subjects (67). 
Consequently, the measurement of C-peptide (3-31) as a companion marker to C-
    28 
peptide is a potential avenue to improve the already gold-standard ID-MS assays, 
and, moreover, the measurement of both C-peptide forms may offer an assay 
simultaneously reflective of insulin production and modulation of DPP-IV 
activity during therapy. Further investigations in larger clinically well defined 
healthy and diabetic cohorts are necessary to gauge the relative behavior of C-
peptide and C-peptide (3-31) and their individual implications in assay 
improvement and disease stratification. 
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Chapter 4 
MASS SPECTROMETRIC IMMUNOASSAY OF INTACT INSULIN AND 
RELATED VARIANTS FOR POPULATION PROTEOMICS STUDIES 
Numerous genetic polymorphisms and splice variants of human insulin have been 
characterized (74-77) [UniProtKB AC P01308]. Yet there remains a need for 
systematic methods to monitor polymorphisms, splice variants, and particularly, 
posttranslational modifications (e.g. degradation products) that are not pre-
defined, in the population at large. Data arising from the application of such 
methods will take us one step closer to making personalized medicine in the 
context of diabetes a reality. 
An essential and differentiating characteristic of mass spectrometric-based 
assays that are designed from a top-down perspective is that immunoreactive 
forms are clearly and immediately evident in the sample and can be independently 
quantified.  Likewise, protein variants that are distinctly monitored in this way are 
in many circumstances the same variants that interfere with classical analytical 
techniques such ELISAs and radioimmunoassays (RIA) (i.e. the variants cross-
reacts with the antibody) or, conceivably, with recent bottom-up quantitative mass 
spectrometric approaches such as LC-MRM, e.g., SISCAPA (Stable Isotope 
Standards and Capture by Anti-Peptide Antibodies) (19). As in the case of the 
latter example, it is the unmodified portions of variants and native protein (in the 
presentation of tryptic fragments) which equally bind to the antibody and cause 
diminished assay specificity. These techniques (e.g. LC-MRM) result in the 
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summation of protein variants, which may or may not have modified biological 
activity. Consequently, an erroneous read on the concentration of the native, bio-
active form a protein may result. Indeed, this was shown with insulin twenty years 
ago where immunoassays where shown to cross-react with proinsulin related 
molecules (78).  (The same phenomenon has been documented recently with 
regard to human brain natriuretic peptide (BNP) (79).) Moreover, a more 
contemporary study showed 11 commercially available insulin assays (one RIA 
and 10 enzyme/chemiluminescent based) to vary by a factor of 2 indicating assay-
specific cross-reactivity (80). Consequently, several groups have responded to this 
challenge with the development of quantitative mass spectrometric insulin assays. 
With the mass spectrometer serving as the detection component of the assay, it is 
now possible to unambiguously quantify intact insulin out of plasma and urine 
distinct from preproinsulin byproducts, insulin degradation products, and 
synthetic insulin analogs (81-85).  While there are some relative advantages to 
previously reported MS techniques including the ability to monitor for unique 
MS2 diagnostic product ion signatures resulting from insulin isoforms (85), assays 
such as these are not suited for large population screenings when the goal is to 
monitor for unanticipated forms of insulin. Herein we report a high-throughput, 
full-scan mode mass spectrometric assay for quantifying insulin which 
simultaneously provides accurate-mass detection of insulin-related protein 
variants that have not been pre-defined. 
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EXPERIMENTAL 
STUDY SUBJECTS, SAMPLE COLLECTION AND PREPARATION 
CDI (1,1'-Carbonyldiimidazole)-activated affinity pipette tips were prepared and 
derivatized with mouse anti-human insulin antibody (AbD Serotec, Cat No. 5329-
3806), as previously described for other antibodies (23, 86). For development of 
the assay, a bulk quantity (> 100 mL) of healthy human EDTA plasma from an 
individual female donor was used. Sixteen additional human EDTA plasma 
samples from patients including 8 healthy individuals and 8 type 2 diabetics (6 ID 
T2D (insulin dependent type 2 diabetics), and 2 non-ID T2D (non-insulin 
dependent type 2 diabetics)) were acquired under IRB approval. Cohorts were 
matched by gender. The diabetic cohort had an average age of 57 and the healthy 
cohort had an average age of 51. Sheep plasma was used as the matrix to generate 
standard curves and was acquired from Bioreclamation, Inc.  All samples were 
stored at -80˚ C prior to use. Upon use, samples were centrifuged for 5 minutes at 
10,500 x g and subsequently re-aliquoted into a 96 well sample tray. Porcine 
insulin, human insulin, and bovine serum albumin were purchased from Sigma-
Aldrich. As qualitative negative controls, anti-resistin and anti-osteocalcin were 
purchased from R&D Systems and Novus Biological, respectively.   
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PLASMA MASS SPECTROMETRIC IMMUNOASSAYS 
Five hundred microliters of human plasma was pre-treated with 250 µL of a 
solution containing: 4.5 % Tween 20, 150mM Octyl-β-glucopyranoside, 1.5M 
Ammonium Acetate, and Concentrated PBS (0.67M sodium phosphate, 1M 
sodium chloride), for a total analytical volume of 750 µL.   Insulin and related 
variants were extracted with the aid of a Beckman Multimek 96 pipetting robot by 
repeatedly (250 repetitions) drawing and expelling (back into the sample volume) 
125-µL aliquots of the sample volume through an anti-insulin affinity pipette. 
After extraction, the pipettes were rinsed using PBS (0.1 M sodium phosphate, 
0.15 M sodium chloride, pH 7.2), HBS-P (0.01 M HEPES, 0.15 M NaCl, 0.05% 
v/v Tween Surfactant P20, pH 7.4), H2O, 100mM Tris HCl 
(Tris(hydroxymethyl)aminomethane hydrochloride pH 4.6), and H2O (in this 
order, each rinse = 10 repetitions of 150 µL), after which insulin was eluted and 
prepared for MALDI-TOF MS by drawing 4 µL of MALDI matrix solution 
(saturated aqueous solution of sinapic acid, in 33% (v/v) acetonitrile, 0.45% (v/v) 
trifluoroacetic acid, TFA) into the pipette and depositing onto a MALDI target.  
 
MASS SPECTROMETRY 
MALDI-TOF MS was performed using a Bruker Ultraflex III MALDI-TOF-MS 
instrument. The instrument was used in both linear mode (for precision 
experiments as explained below) and with reflector engaged. In the former, 
positive ion, delayed-extraction mode was used with ‘ionsource 1’ at 25.00 kV, 
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‘ion source 2’ at 23.50 kV, lens at 6.00 kV, 50 ns delayed extraction, deflection 
signal suppression up to m/z 2500, and 1 GS/s sample rate. When the reflector 
was engaged, the instrument operated in the positive ion, delayed-extraction mode 
with ‘ion source 1’ at 25.00 kV, ‘ion source 2’ at 21.90 kV, lens at 9.50 kV, 
‘reflector’ at 26.30 kV, ‘reflector 2’ at 13.80, 190 ns delayed extraction, 
deflection signal suppression up to m/z 2000, and 2 GHz sampling rate. At least 
10 thousand laser-shots were signal averaged for each mass spectrum to ensure 
good ion counting statistics. In linear mode, spectra were externally calibrated 
with a mixture of 4 proteins, supplied by Bruker (Cat. No. 208241), ranging from 
m/z 5734.52 (Insulin [M+H]+ to m/z 12,360.97 (Cytochrome C [M+H]+. When in 
reflector mode, MALDI-TOF-MS mass spectra were externally calibrated with a 
mixture of peptides and proteins supplied by Bruker including: m/z 2093.086 
(ACTH_clip(1-17) [M+H]+; monoisotopic), m/z 3147.471 (Somatostatin [M+H]+; 
monoisotopic), m/z 5730.609 (Bovine Insulin [M+H]+; monoisotopic), and m/z 
6179.67 (Cytochrome C [M+2H]2+; most abundant isotope).  
 
INSULIN QUANTIFICATION 
All samples used for quantification were fortified with 150 pM porcine insulin 
(which served as the internal standard) prior to extraction of endogenous human 
insulin. Samples used in the generation of insulin standard curves were prepared 
and assayed using sheep plasma diluted 4x in 30 g/L BSA in HBS-N (0.01M 
HEPES and 0.15M NaCl). The curves were prepared (via serial dilution) with a 
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human insulin concentration range of 15 pM to 1.92 nM. The curves had 9 
concentration points in total, including the blank samples with only internal 
standard. For insulin quantification out of human samples, eight EDTA plasma 
samples from healthy volunteers and eight EDTA plasma samples from T2D 
volunteers were run in parallel with a standard curve. On each day of the 
interday/intraday precision experiment, curves were run in triplicate alongside 
samples with known concentrations of human insulin, at 50 pM (n=4), 100 pM 
(n=4), and 400 pM (n=4). Samples were prepared fresh daily. 
 
DATA PROCESSING 
Individual mass spectra were baseline subtracted (Tophat algorithm) and 
smoothed (SavitzkyGolay algorithm; width = 0.2 m/z; cycles = 1) prior to peak 
integration using Bruker Daltonics flexAnalysis 3.0. All peaks representing 
porcine insulin, intact insulin, and insulin variants were integrated baseline-to-
baseline (using Intrinsic Bioprobes Inc. Zebra 1.0) and tabulated in a spreadsheet 
for quantification. 
 
REDUCTION OF INSULIN  
On-target reduction of interchain disulfide bonds was employed to verify the 
identification of insulin in the mass spectrum: The target (96-well format 
MALDI-TOF-MS gold coated plate) was placed on a 40°C heating plate followed 
by application of a three-microliter aliquot of 100mM dithiothreitol (DTT) in 
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100mM tris base (pH 8.5) to an already-dried MALDI spot previously shot from a 
healthy human sample. Reduction was carried out for 20 minutes, during which 
time the aqueous environment of the samples was maintained by the addition of a 
1 µL aliquot of water at the beginning of the reduction and every 4 minutes 
thereafter. The reduction reaction was terminated after 20 minutes via the addition 
of a 3-µL aliquot of the MALDI matrix solution which lowered the pH down to 
~1-2. This effectively ended the reduction process and, upon air-drying, 
recrystallized the matrix spot. 
 
RESULTS AND DISCUSSION 
In the development phase of the assay prior to the implementation of internal 
standards for quantification, various sample preparations and rinses were tested. 
Figure 4(I) shows a pre-optimized MSIA spectrum without the use of in-sample 
detergents, salts, and post-extraction rinses. Tween 20, Octyl-β-glucopyranoside, 
Ammonium Acetate, and PBS were determined, when added to the plasma 
sample, to minimize the non-specific binding of proteins. Next, various rinse 
protocols were tested. It was determined that PBS, HBS-P, H2O, 100 mM Tris-
HCl, and finally H2O produced the best results. Figure 4(II) shows an optimized 
MSIA spectrum. Overall, the optimized protocols produced spectra largely free of 
non-targeted proteins, high S/N ratios, and isotopic resolution for insulin. The 
open m/z window that was created after the optimization was valuable for the 
potential detection of additional insulin isoforms that were cross-reactive with the 
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antibody. Figure 4(III) shows an on-target-reduction spectrum of insulin. 
Notably, this was generated by reducing the same MALDI matrix spot used to 
generate Figure 4(II). Reduction of insulin breaks the two-disulfide bonds 
between the α-chain and β-chain and the single disulfide bond within the α-chain.  
Besides the specificity imparted by antibody capture and verified by the exact 
mass detection of intact insulin, the observation of exact masses corresponding to 
the α- and β-chains of insulin upon reduction confirm the qualitative specificity 
of the assay. Lastly, an additional measure ensuring assay specificity was 
achieved by generating a MALDI-TOF/TOF (MS/MS) spectrum on the insulin β-
chain (Figure 5; methodology described elsewhere (87)). This was produced 
from a healthy human sample that had 50 nM recombinant human insulin spiked 
in pre-extraction (endogenous insulin levels did not produced adequate S/N for 
MS/MS).  
An analog of a protein that has a different molecular weight may be used as an 
internal standard for quantification when using MALDI-TOF-MS (25). In this 
manner, the internal standard is captured with the target protein using the same 
antibody (the antibody must be able to cross-react). While an internal standard 
can be a chemically modified form of a protein (25), the use of a protein from a 
different species may be used provided they differ enough in m/z (18). 
Considering the monoisotopic mass of human insulin at 5804.65 Da [M+H]+ and 
a mass resolution of 15,000 (m/∆m; FWHM), porcine insulin was determined to 
be an excellent internal standard which differs in mass from human insulin by -
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30.01 Da (the monoisotopic molecular weight is 5774.64 Da [M+H]+). This 
change in mass results from the presence of an alanine (rather than threonine) 
residue at the β-30 position of porcine insulin.  The anti-human insulin antibody 
employed in these studies was developed with human insulin as the immunogen 
and is known to recognize insulin and pro-insulin, but the binding epitope has not 
been determined.  Porcine insulin proved to be, retrospectively, well chosen due 
to its distinct mass relative to synthetic insulin analogs and natural insulin 
degradation products.  
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Figure 4: Development of the insulin MSIA. I) The insulin MSIA in the 
development phase. Plasma from a healthy individual was used (endogenous 
insulin extracted) to optimize protocols involved in removing non-specific 
proteins. Non-specific signals include Apolipoprotein C-I and residue found 
within the antibody solution. II) An optimized spectrum resulting from the use of 
in-sample detergents, salts, and post-extraction rinses. III) The MALDI-TOF-MS 
spot used to generate (II) was reduced on-target to verify specificity of the 
antibody via the appearance of the insulin α-chain and insulin β-chain. * 
corresponds to sinapic acid matrix adducts. The “1” label on the y-axis indicates 
100% relative abundance for the spectrum shown. 
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Insulin MSIA curves demonstrated excellent linearity (the average r2 value for 
all three days was 0.9983). The limit of detection (LOD) and limit of 
quantification (LOQ) were found to be 1 pM and 15 pM, respectively, provided 
that at least 500 μL of plasma were employed for the assay. Three sample sets 
composed of four samples each with concentrations of 50 pM, 100 pM, and 
400pM were used for intra/inter-assay precision experiments conducted over three 
days (Table 2). The intraday CVs and estimated interday CVs were < 8%. A 
Figure 5: MALDI-TOF/TOF (MS/MS) of Insulin β-chain. A healthy human 
sample was spiked with human insulin at 50 nM and was subsequently 
immunoprecipitated with MSIA, reduced on the MALDI target, and then analyzed 
by MALDI-TOF/TOF (MS/MS) for assay specificity confirmation. b-ions, y-ions 
and their corresponding sequence tags are shown.  The sequence of human insulin 
β-chain is: H2N-FVNQHLCGSHLVEALYLVCGERGFFYTPKT-CO2H. 
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typical standard curve regression line was described by the equation y = 2.096x – 
0.034.  Using the multi-day data from the triplicate working curves run each day, 
the average standard error of the estimate was determined to be 24 pM. We 
estimate the actual captured amount of insulin to be in the range of 1 fmol at the 
LOQ. A typical standard curve is presented in Figure 6. 
Figure 7 presents MALDI-TOF-MS spectra obtained in reflector mode from 
human samples using the insulin MSIA. In this figure, human insulin, des-thr30-
insulin (β-chain), des-arg32-31-Lantus (β-chain), and porcine insulin (internal 
standard) are shown. Intact Lantus and intact Novolog were also detected in the 
T2D patient samples.  With the exception of one outlier, mass accuracy of insulin 
variants detected was 15 ± 7 ppm (Table 3).  With this degree of mass accuracy 
(< 5 ppm with internal mass calibration) and knowledge of the identity and 
sequence of the target protein (imparted by the specificity of the capture-
antibody), mass mapping can greatly narrow a list of candidate protein 
modifications.  Monoisotopic peak assignments were used when S/N was >3. 
When monoisoptic peaks did not meet this criteria (as in the case of intact 
Lantus), the most abundant isotope was used for assignment. Of note, we were 
unable to generate MS/MS information on reduced insulin isoforms due to their 
low concentrations. Negative control experiments were run using T2D samples 
known to have des-thr30-insulin (β-chain), Lantus, and Novolog present using 
MSIA tips derivatized with anti-resistin and anti-osteocalcin. Insulin-related 
proteins were not detected. 
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Conc.    
(pM) 
Day 1 (n = 4) Day 2 (n = 4) Day 3 (n = 4) Inter-day (n = 3 days) 
50 57.1 ± 2.8; 5.0% 48.8 ± 2.9; 5.9% 52.0 ± 3.2; 6.1% 52.6 ± 4.1; 7.9% 
100 98.5 ± 0.9; 0.9% 86.6 ± 4.4; 5.1% 96.2 ± 4.3; 4.5% 93.8 ± 6.3; 6.7% 
400 388.5 ± 5.3; 1.4% 347.5 ± 30.0; 8.6% 389.0 ± 10.0; 2.6% 375.0 ± 23.8; 6.4% 
Table 2: Three samples (n = 4 ea.) with known concentrations of 50 pM, 100 pM, and 400 pM 
were tested using the insulin MSIA on three separate days (intra-assay precision). Using these 
data (n = 3 days), inter-assay precision values were calculated. Values correspond to the average 
concentration ± standard deviation and to the percent coefficient of variation. 
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Figure 5: Representative insulin MSIA working curve. 
 
The healthy and diabetic cohorts had an average intact insulin concentration 
and standard deviation (SD) of 82 ± 60 pM and 243 ± 359 pM, respectively. The 
range for the two cohorts were 15 – 176 pM and 32 – 1116 pM, respectively.  
Sample concentrations in the healthy cohort were not clustered near the LOQ and 
only one sample was found to have a concentration of 15 pM.  Basal insulin 
concentrations in healthy humans are typically in the range of 30-90 pM, with a 
peak rise to 360-540 pM during meals (88).  This is consistent with our 
measurements of intact insulin in healthy individuals.  Outlier samples below 15 
pM intact insulin concentration would have to be quantified by an alternative 
assay, then coupled with the qualitative assay presented here to determine the 
presence of molecular heterogeneity. 
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Figure 7: Insulin MSIA spectra from diabetic samples. m/z values refer to the 
monoisotopic mass [M+H]+: human insulin (observed 5804.57 m/z, theoretical 
5804.65); des-thr30-insulin (β-chain) (observed 5703.55, theoretical 5703.60); 
porcine insulin (internal standard) (observed 5774.66, theoretical 5774.64); and 
des-arg32-31-Lantus (β-chain) (observed 5747.50, theoretical 5747.63). 
 
    44 
Isoform Observed Theoretical 
Endogenous     
     Intact Human Insulin 5804.57 5804.65 
     Des-Thr
30
-Insulin (β-chain)  5703.55 5703.60 
Exogenous     
     Novalog 5822.59 5822.62 
     Lantus
a 6063.13 6062.85 
     Des-Arg
32-31
-Lantus (β-chain) 5747.50 5747.63 
Intact Human Reduced     
     α -chain 2382.95 2383.00 
     β -chain 3428.75 3428.69 
 
 
 
 
The known urinary metabolite of insulin, des-thr30-insulin (β-chain) (89), was 
detected in the plasma of three diabetics and the truncated form of Lantus was 
detected in the plasma of one diabetic. To our knowledge, these variants have 
previously only been detected in urine.  Sample MSIA spectra for healthy and 
T2D patients are presented in Figure 8. 
 
Table 3: List of all insulin heterogeneity encountered within this study. 
m/z values reflect MALDI-TOF-MS monoisotopic detection. a denotes X + 3 
isotope used for mass determination. 
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The research described here was designed to operate as a precursor to future, 
large-population based studies. In this manner, hundreds of samples (and 
eventually thousands) will be screened to establish the natural variation of insulin 
molecules in the general population. (Using the MSIA technology, a single mass 
spectrometer, and a single robotic pipette station, it takes 2 hours to generate data 
per 96-well sample plate. Accordingly, 480 data points can be acquired in each 
sample run resulting from the analysis of the 5 distinct insulin isoforms mentioned 
in this study. Using conventional methods (e.g. ELISA), five distinct assays 
would be required to capture the same information content and would take 
significantly longer.) Accordingly, due to the choice of analysis by MALDI-TOF-
MS, an open m/z window surrounding intact insulin in every acquired spectrum 
may provide the opportunity for unreported variations of the molecule to reveal 
themselves when larger populations are scrutinized. In this framework, new 
Figure 8: Comparison of representative Healthy versus T2D insulin 
MSIA spectra. 
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isoforms and perhaps the isoforms discussed here (e.g. metabolic products, des-
thr30-insulin (β-chain); proinsulin byproducts) may engender clinical utility in the 
form of biomarkers. Such clinically applied insulin heterogeneity would be 
exciting considering the preexisting scope of the molecule’s history including its 
discovery ninety years ago (90) and well-established biology.  
 
 
 
 
 
  
    47 
Chapter 5 
INSULIN AND C-PEPTIDE MASS SPECTROMETRIC IMMUNOASSAY 
DEVELOPMENTS 
In our previous mass spectrometric immunoassay (MSIA) population screenings 
for Insulin and separately, C-peptide (20, 91), we detected a total of nine 
endogenous and exogenous (i.e. therapeutic) variants found in plasma: C-peptide 
(1-31), C-peptide (2-31), C-peptide (3-31), C-peptide (4-31), Intact Insulin, 
Insulin Des (B30), Lantus, Lantus Des (B32-21), and Novalog. In particular, C-
peptide (3-31) was discovered and shown be associated with diabetes. Serving to 
present recent assay efforts towards unifying these two assays, here we report the 
development of a quantitative multiplexed mass spectrometric immunoassay 
(MSIA) that offers monoisotopic MALDI-TOF-MS of all reported insulin and C-
peptide variants. The assay is based on a two-antibody system that simultaneously 
targets C-peptide and insulin and their respective variants and internal standards, 
and is intrinsically capable of detecting any additional variants that may surface in 
future large-scale population screenings. Herein, we describe the quantification 
specifications of the multiplexed assay, example quantification data from human 
samples, and oral-glucose tolerance test (OGTT) results from two health human 
samples. Notably, multiple-protein and variant quantification is considered 
beyond what is technically feasible with conventional assay approaches (e.g. 
ELISA). Lastly, when the assay is applied in MS/MS mode, a novel way to 
quantify proteins using MALDI is achieved. Using this methodology, a higher 
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degree of specificity is realized by simultaneously monitoring daughter ions 
resulting from single intact parent molecules (e.g. daughter ions from C-peptide 
(1-31)) and it’s respective internal standard: heavy C-peptide (1-31)). As such, 
this work establishes a foundation for the qualitative and quantitative analysis of 
intact, low-abundant, protein and/or peptide isoforms via simultaneous detection 
using MSIA.  
 
EXPERIMENTAL 
Of note, this experimental section closely follows the two prerequisite population 
studies (16, 20). 
STUDY SUBJECTS, SAMPLE COLLECTION AND PREPARATION 
CDI (1,1'-Carbonyldiimidazole)-activated affinity pipette tips were prepared and 
derivatized with mouse anti-human C-peptide and Insulin antibody (AbD 
Serotec), as previously described (20, 91), with the exception that both antibodies 
were mixed at a ratio 1:2, respectively.  For the development of the assay, healthy 
human female plasma was purchased from ProMedDx (Norton, MA). Five 
hundred microliters of human plasma  was pre-treated with 250 µL of a solution 
containing: 4.5 % Tween 20, 150mM Octyl-β-glucopyranoside, 1.5M Ammonium 
Acetate, and Concentrated PBS (0.67M sodium phosphate, 1M sodium chloride), 
for a total analytical volume of 0.75 mL.  
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SAMPLES 
All samples used for quantification were fortified with 150 pM porcine insulin 
(which served as the internal standard), 100 pM heavy C-peptide (1-31), and 1 
nM heavy C-peptide (3-31), prior to extraction of endogenous human insulin and 
C-peptide. “Heavy” refers to heavy-isotope peptides manufactured using C13 
modified leucine residues (received as a gift from Thermofisher Scientific). 
Samples used in the generation of insulin standard curves were prepared and 
assayed using sheep plasma diluted 4x in 30 g/L BSA in HBS-N (0.01M HEPES 
and 0.15M NaCl). The curves were prepared (via serial dilution) with an insulin 
concentration range of 15 pM to 1.92 nM, a C-peptide concentration range from 
117 pM to 15 nM, and a C-peptide (3-31) concentration range from 47 pM to 3 
nM. The curves had 9 concentration points in total, including the blank samples 
with only internal standard. For insulin and C-peptide quantification out of human 
samples, six EDTA plasma samples and two OGTT sample sets from healthy 
volunteers were run in parallel with a standard curve. Regarding the OGTT 
sample sets, the two individuals were healthy males of Asian ancestry with no 
reported history diabetes mellitus between the ages of 25 and 60. Patients were 
subjected to an OGTT wherein samples were collected at different time points (0, 
30, 60, 90 and 120 min) after a 75g oral glucose load (with the exception of the 
time point zero occurring immediately prior to ingestion). 
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PLASMA MASS SPECTROMETRIC IMMUNOASSAYS 
C-peptide and Insulin were extracted with the aid of a Beckman Multimek 96 
pipetting robot by repeatedly (250 repetitions) drawing and expelling (back into 
the analytical volume) 125 µL aliquots of the analytical volume through an anti-
C-peptide/Insulin affinity pipette. After extraction, the pipettes were rinsed using 
PBS (0.1M sodium phosphate, 0.15M sodium chloride, pH 7.2), HBS-P (0.01M 
HEPES, 0.15M NaCl, 0.05% v/v Surfactant P20, pH 7.4), H2O, 100mM 
Tris(hydroxymethyl)aminomethane hydrochloride (pH 4.6), and H2O (in this 
order, each rinse = 10 repetitions of 150 µL), after which C-peptide and Insulin 
were eluted and prepared for MALDI-TOF MS by drawing 4 µL of MALDI 
matrix solution (saturated aqueous solution of sinapic acid, in 33% (v/v) 
acetonitrile, 0.45% (v/v) trifluoroacetic acid, TFA) into the pipette and depositing 
onto a MALDI target 
 
MASS SPECTROMETRY 
When exclusively analyzing C-peptide, MALDI-TOF MS was performed using a 
Bruker Ultraflex MALDI-TOF instrument operating in the negative ion, delayed-
extraction mode; reflector engaged with ‘ion source 1’ at 20.00 kV, ‘ion source 2’ 
at 17.45 kV, lens at 7.50 kV, ‘reflector’ at 21.00 kV, ‘reflector 2’ at 10.95, 60 ns 
delayed extraction, deflection signal suppression up to m/z 1500, and 2 GS/s 
sample rate. Two hundred laser-shots were signal averaged for each mass 
spectrum.  Single stage MALDI-TOF mass spectra were externally calibrated 
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with a mixture of 6 peptides supplied by Bruker (Cat. No. 208241) ranging in 
monoisotopic m/z from 1044.53 (Angiotensin II [M-H]-) to 3145.46 (Somatostatin 
[M-H]-). When analyzing both C-peptide and Insulin simultaneously, the 
instrument was used in both linear mode and with reflector engaged. In the 
former, positive ion, delayed-extraction mode was used with ‘ion source 1’ at 
25.00 kV, ‘ion source 2’ at 23.50 kV, lens at 6.00 kV, 50 ns delayed extraction, 
deflection signal suppression up to m/z 2500, and 1 GS/s sample rate. When the 
reflector was engaged, the instrument operated in the positive ion, delayed-
extraction mode with ‘ion source 1’ at 25.00 kV, ‘ion source 2’ at 21.90 kV, lens 
at 9.50 kV, ‘reflector’ at 26.30 kV, ‘reflector 2’ at 13.80, 190 ns delayed 
extraction, deflection signal suppression up to m/z 2000, and 2 GHz sampling 
rate. At least 10 thousand laser-shots were signal averaged for each mass 
spectrum to ensure good ion counting statistics. In linear mode, spectra were 
externally calibrated with a mixture of 4 proteins, supplied by Bruker (Cat. No. 
208241), ranging from m/z 5734.52 (Insulin [M+H]+ to m/z 12,360.97 
(Cytochrome C [M+H]+. When in reflector mode, MALDI-TOF-MS mass spectra 
were externally calibrated with a mixture of peptides and proteins supplied by 
Bruker including: m/z 2093.086 (ACTH_clip(1-17) [M+H]+; monoisotopic), m/z 
3147.471 (Somatostatin [M+H]+; monoisotopic), m/z 5730.609 (Bovine Insulin 
[M+H]+; monoisotopic), and m/z 6179.67 (Cytochrome C [M+2H]2+; most 
abundant isotope).  
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DATA PROCESSING 
Individual mass spectra were baseline subtracted and smoothed prior to peak 
integration.  Peaks representing the five most abundant C-peptide and C-peptide-
variant isotopes were integrated and tabulated in a spreadsheet for quantification. 
All peaks representing porcine insulin, intact insulin, and insulin variants were 
integrated baseline-to-baseline and tabulated in a spreadsheet for quantification. 
For MS/MS quantification of C-peptide, S/N values were used for quantification. 
QUANTIFICATION VIA TANDEM MASS SPECTROMETRY 
LIFT-TOF/TOF mass spectra of C-peptide (1-31) and heavy C-peptide (1-31) 
from working curve samples were acquired on a Bruker Ultraflex MALDI-
TOF/TOF instrument in positive ion mode using sinapic acid as a matrix.  
Precursor ions were selected within a 15 Da mass window. At least 20 thousand 
laser-shots were signal averaged for each mass spectrum to ensure good ion 
counting statistics. The LIFT-TOF/TOF instrument control method was calibrated 
according to the instrument manufacturer’s protocol and was run without CID 
gas. 
 
RESULTS AND DISCUSSION 
The assay is based on a two-antibody system that simultaneously targets C-
peptide and insulin and their respective variants and internal standards. Figure 9 
shows the results of the multiplexed MSIA performed in order to evaluate 
performance when applied to human plasma (without benefit of added internal 
    53 
standards). Excellent signal to noise was observed for the endogenous wild-type 
C-peptide and insulin. Non-specific binding was minimal, and the regions around 
both C-peptide and insulin were relatively clear of other species, which allowed 
for the detection of mass-shifted variants – i.e., both endogenous and exogenous 
(insulin-based therapeutics). Using the (non-internal standard) assay in previous 
 
  
 
 
 
 
Figure 9: Multiplexed C-peptide and Insulin spectrum. Multiplexed C-peptide 
(observed 3019.91 m/z, theoretical 3019.521) and insulin (observed 5804.65 m/z, 
theoretical 5804.65 m/z) MSIA performed in order to evaluate performance when 
applied to human plasma. * Denotes non-specific binding. 
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qualitative population screenings (n = 108) (20, 91), a total of nine variants 
related to C-peptide and insulin were observed [C-peptide (1-31), C-peptide (2-
31), C-peptide (3-31), C-peptide (4-31), Intact Insulin, Insulin Des (B30), Lantus, 
Lantus Des (B32-21), and Novalog]. Other than cataloging variants, this exercise 
scrutinized the mass ranges surrounding the wild-type species so that internal 
standards could be judiciously chosen so not to interfere with the quantification of 
the plasma-borne variants. Notably, C-peptide (3-31) is a particular isoform that 
we previously discovered and found associated to diabetes (91). This variant 
likely has implications for diabetic therapeutics, as we hypothesized it is produced 
via the truncation of intact C-peptide (1-31) via Dipeptidyl Peptidase-4 (DPP-IV), 
an enzyme responsible for regulating glucose metabolism (40, 67, 92). Insulin 
(20), C-peptide (1-31), and the newly discovered C-peptide (3-31) were 
quantified. Figure 10 shows the results of both C-peptide variants and their 
respective heavy-isotope internal standards being captured from plasma. Of note, 
the four C-peptide isoforms identified thus far were found to have an equal 
binding affinity in limit of detection experiments using purified recombinant 
standards (data not shown). Consequently, use of multiple internal standards for 
C-peptide isoform quantification may be superfluous when the assay is run in 
intact parent-ion quantification mode as apposed to MS/MS quantification mode, 
as explained below. The six health human samples assayed had insulin and C-
peptide average concentrations of 37 ± 18 pM and 1.7 ± 0.56 nM, respectively.  
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Lower limits of detection of the multiplexed assay ranged from 1 – 12.5 pM, 
dependent on the variant. Quantitative standard curves for intact insulin and C-
peptide (and variants) exhibited good dynamic range and linearity (dynamic range 
= 1000, average R2 for three consecutive days of analysis = 0.99). Limits of 
quantification ranged from 15pM - 15nM. Figure 11 presents an example 
working curve for C-peptide (3-31) with actual spectra representing a set of points 
comprising the working curve.  
 
 
Figure 10: Dual-capture of light and heavy C-peptide variant standards. C-
peptide (1-31) (observed 3017.51 m/z, theoretical 3017.51 m/z) and C-peptide (3-
31) (observed 2817.45 m/z, theoretical 2817.45 m/z) variants and their respective 
heavy-isotope internal standards captured from plasma (observed 3024.52, 
theoretical 3024.46 m/z; observed 2824.46, theoretical 2824.40 m/z, respectively) 
being captured from plasma.  
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The assay was subsequently applied to two sets of OGTT samples 
(representing two individuals) in five thirty-minute intervals (Figure 12). An 
OGTT is clinical test whereby an individual ingests 75 grams of glucose with 
concurrent sample collection across multiple time points (with time point zero 
representing the moment before ingestion). The intent is to monitor for the 
clearance of glucose from the blood stream and ultimately for the presence of 
diabetes (i.e. high basal glucose levels). 
 
 
 
 
 
 
 
 
 
 
 
 
 
As one might expect, certain variations of this test also include monitoring for 
insulin and C-peptide (93). We thought it would be of clinical relevance to 
Figure 11. C-peptide (3-31) quantitation. The working curve for 
truncated c-peptide (c-peptide (3-31) and overlaid MALDI spectra for each 
point on the line (R2 = 0.99).  
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monitor insulin and C-peptide and any respective isoforms. Of note, the samples 
were captured using Bd P800 collection tubes (94) which contain a proprietary 
inhibitor cocktail. These tubes are used to prevent the degradation of endocrine 
hormones responsible for glucose metabolism (of note, DPP-IV is a key enzyme 
targeted). The two subjects were healthy males of Asian ancestry between the 
ages of 25-60. Both subjects displayed ordinarily observed OGTT trends, which 
include an insulin and C-peptide spike in response to the ingested glucose 
followed by a steady decrease. However, subject 2 displayed a delayed response 
with substantial increases in insulin and C-peptide release, with still-heightened 
levels towards the conclusion of the test. Previous studies have shown age 
influences the results of this test (93), and as such, we hypothesize subject 2 was 
older and than subject 1. Likely due as a result of the inhibitor cocktail, C-peptide 
(3-31) was not observed in any samples, which again, we suspect is an enzymatic 
product generated by DPP-IV. Interestingly, C-peptide (4-41) was detected in 
both samples and demonstrated a similar trend as observed with C-peptide and 
insulin. 
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Figure 12:  Oral glucose tolerance test results for two healthy individuals. 
Intact insulin, C-peptide (1-31), C-peptide (4-31) were quantified at five time 
points over a timespan of 120 minutes.  
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Figure 13 introduces preliminary data on a novel way to quantify proteins and 
peptides using MALDI-TOF/TOF (MS/MS). This approach is akin to the 
Multiple Reaction Monitoring (MRM) mass spectrometric technique whereby a 
protonated peptide undergoes multiple stages of separation within a triple 
quadruple mass spectrometer, ultimately becoming fragmented and detected via 
the unique daughter-ions signatures. As presented here, the MALDI-TOF/TOF 
(MS/MS) precursor selection window is set wide enough to allow the native 
protein and/or peptide and the corresponding internal standard to enter the flight-
Figure 13: MALDI-TOF/TOF (MS/MS) quantitative working curves. In 
this figure the y-16 and y-17 working curves are presented with R2 = 0.99 for 
both curves. Notably, these y-ions shift for discovered C-peptide variants (e.g. 
C-peptide 3-31). The sequence of human C-peptide is H2N- 
EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ-CO2H.  
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tube and become fragmented simultaneously. In the illustrated example, C-
peptide is quantified at physiological concentrations via two separate working 
curves: the y-16 C-peptide ion and the y-17 C-peptide ion. Both ions exhibited 
good linearity (R2 = 99). To the best of our knowledge, this form of quantification 
using MALDI has not been presented in the literature. Although this approach to 
MALD quantification may be viewed as extraneous if one acknowledges the 
specificity imparted by the antibody, the relatively high resolution (e.g. 15,000 for 
insulin; m/Δm; FWHM), and the lack of interference shown by control 
experiments, it’s conceivable that certain clinical applications may require higher 
degree of assay specificity as a precautionary measure (e.g. 1 out of 500 patients 
have a blood-borne a non-specific protein that interferes with the assay). For 
example, if an interfering signal registering at 3017.50 m/z (the mono-isotopic 
molecular weight of C-peptide (1-31) in negative-ion mode) was proven to be 
non-specific, this could be bypassed by quantifying via C-peptide daughter-ions 
(notably, we have found no evidence of assay inference for insulin or C-peptide). 
As an added benefit to using this approach, suppression effects should to be 
substantially diminished which allow for increased sensitivity. Although only one 
protein or peptide can be quantified per laser shot fired, future iterations of 
MALDI-TOF are suspected to be capable of monitoring many proteins 
simultaneous, akin to a triple-quadruple but with full-scan and high m/z 
proficiencies inherent with MALDI-TOF. 
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Future studies will be focused on establishing the physiological quantification 
range of endogenous insulin and C-peptide metabolites with the use of thousands 
of samples within the context of diabetes and related diseases.  
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Chapter 6 
INTRAPERSONAL AND POPULATIONAL HETEROGENEITY OF THE 
CHEMOKINE RANTES 
Chemokines are essential to the initiation and maintenance of inflammation. They 
perform their duty via the mechanisms of chemotaxis whereby leukocytes are 
attracted to higher gradients of chemokines. More than forty chemokines and 
twenty chemokine receptors have been identified. The chemokine superfamily is 
broken up into four main groups (C, CC, CXC, and CX3C); this is based upon the 
position of the first two cysteine residues in a conserved four-cysteine motif found 
pervasively among chemokines (RANTES is a CC chemokine, hence its 
alternative name: CCL5) (95). The receptors are G-protein coupled, seven-
transmembrane receptors named accordingly to the class of chemokine they bind 
(e.g. RANTES/CCL5 binds to the CCRX receptor subset) (96). Proinflammatory 
chemokine receptors tend to have less discriminative ligand binding specificities 
whereas receptors involved in normal leukocyte trafficking have higher 
specificities (96-98). RANTES (which stands for Regulated on Activation, 
Normal T cell Expressed and Secreted) binds to CCR1, CCR3, CCR5, and DARC 
receptors and correspondingly has an integral role in inflammation, cell 
recruitment, and T cell activation. RANTES can be released from multiple 
sources, including activated T lymphocytes and monocytes/macrophages, 
epithelial cells, bronchial epithelium, and dermal fibroblast and renal tubular 
epithelium (99).  The native-wild type is composed of 68 amino acids and has a 
    63 
molecular weight of 7847 Da with both disulfide bonds intact (notably, the signal-
containing protein is 91 a.a. in size). To date, there are two well-established 
RANTES variants: truncated versions comprised of residues [3-68] and [4-68]. 
These variants are the products of two separate regulatory enzymes (Dipeptidyl 
Peptidase IV and Cathepsin G, respectively) and have modified chemotactic and 
antiviral functionality compared to that of intact RANTES (100, 101). 
Furthermore, there is evidence that an O-linked glycosylated RANTES variant 
may exist (102). Consequently, research concerned with RANTES, which was 
discovered in 1988 via a cDNA study of T-cells (103), has in a short amount of 
time begun to unravel a molecule of depth that appears to be connected to an 
array of pathophysiological  conditions that arise in humans. 
The clinical significance of RANTES is considerable as it has been associated 
with many diseases including kidney related complications (e.g. renal failure and 
renal cancer), autoimmune diseases (e.g. arthritis, diabetes, and 
glomerulonephritis), sepsis-induced disseminated intravascular coagulation in 
infants, and several forms of carcinoma including breast and cervical cancer (99, 
104-106). Indeed, plasma RANTES concentrations have been found increased in 
order of cancer stage (I, II, III, or IV) (99). Furthermore, a large population study 
found RANTES in higher plasma concentrations in subjects with Type 2 diabetes 
and impaired glucose tolerance (IGT) relative to healthy controls (107).  
Concerning its role in viral disease, RANTES was discovered to be an effective 
antiviral agent that restricts the entry of CCR5-tropic HIV-1 strains by means of 
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the CCR5 receptor (100). The 3-68 variant form of RANTES was subsequently 
found to also inhibit HIV to the same degree but lacked the same binding affinity 
to the CCR1 receptor. Thus, the impact of RANTES microheterogeneity in 
biological systems stands to be as important as its quantitative fluctuation.   
Commercially available RANTES assays exist widely as enzyme-linked 
immunosorbent assays (ELISAs) and appear to be the primary tool for non-
variant-specific quantification of plasma RANTES in disease-related studies (99, 
108, 109). For reference, one such assay has a sensitivity of 2 ng/L, a measuring 
range of 31.2-2000 ng/L, and intra-assay and inter-assay coefficient of variations 
(CV) of 3.6% and 10.3%, respectively (109). Healthy circulating plasma 
concentrations appear to be around 3 μg/L (99). The ELISA approach lacks the 
intrinsic ability to differentiate between wild-type and variant forms of RANTES. 
The consideration of microheterogeneity, however, may help to explain potential 
measurement discrepancies found between assays. This additional element of 
multiplexed variant detectability enables a view of the genetic and 
posttranslational variants of proteins, which may have significant diagnostic value 
in personalized medicine. Indeed, McIntosh writes “Researchers should be 
encouraged to evaluate and report as a secondary or even primary analysis the 
natural variation of the proteome in the clinical biosamples they analyze ” (110).   
Thus, future quantitative studies of RANTES stand to benefit from a more 
complete survey of qualitatively different variants of RANTES as they exist in 
healthy and diseased populations. Toward this end, this report focuses on 
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mapping the structural differences of RANTES found in a variety of diseases.  As 
a result it provides an alternative qualitative and semi-quantitative method for 
high throughput population-based analysis of RANTES and may assist in the 
expanding our understanding of this molecule’s complex nature in biological 
systems. 
 
EXPERIMENTAL 
STUDY SUBJECTS, SAMPLE COLLECTION AND PREPARATION 
CDI (1,1'-Carbonyldiimidazole)-activated affinity pipette tips were prepared and 
derivatized with mouse monoclonal anti-human RANTES antibody (R&D 
Systems), as previously described for other antibodies (23). For the development 
of the assay, bulk healthy human female plasma from a healthy donor was used. 
Two hundred and thirty nine additional human samples were acquired under IRB 
approval and grouped into non-overlapping cohorts as follows: 37 healthy 
individuals (plasma), 29 healthy individuals (serum), 50 type 2 diabetics (T2D) 
(plasma), 25 individuals with congestive heart failure (CHF) and T2D (plasma), 
17 individuals with CHF, a history of myocardial infarction (hMI), and T2D 
(plasma), 25 individuals with CHF and hMI (plasma), 29 individuals with only 
CHF (plasma), and 27 individuals with cancer (prostate, breast, and colon cancer; 
plasma).  In all plasma samples EDTA was used as the anticoagulant. Cohorts 
were age and sex matched. Two hundred and thirty microliters of human plasma 
was pre-treated with 115 µL of a detergent solution containing: 4.5 % Tween 20, 
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150mM Octyl-β-glucopyranoside, 1.5M Ammonium Acetate, and concentrated 
PBS (0.67M sodium phosphate, 1M sodium chloride), for a total analytical 
volume of 345 µL. Negative control MSIA tips were immobilized with 
monoclonal anti-human C-peptide and Insulin antibody (AbD Serotec). 
PLASMA MASS SPECTROMETRIC IMMUNOASSAYS 
RANTES was extracted with the aid of a Beckman Multimek 96 pipetting robot 
by repeatedly (500 repetitions) drawing and expelling (back into the analytical 
volume) 125 µL aliquots of the analytical volume through an anti-RANTES 
affinity pipette. After extraction, the pipettes were rinsed using HBS-P (0.01M 
HEPES, 0.15M NaCl, 0.05% v/v Surfactant P20, pH 7.4), H2O, 100mM 
Tris(hydroxymethyl)aminomethane hydrochloride (pH 4.6), and H2O (in this 
order, each rinse = 10 repetitions of 150 µL), after which RANTES was eluted 
and prepared for MALDI-TOF MS by drawing 4 µL of MALDI matrix solution 
(saturated aqueous solution of sinapic acid, 33% (v/v) acetonitrile, 0.45% (v/v) 
trifluoroacetic acid, TFA) into the pipette and depositing onto a MALDI target.  
 
MASS SPECTROMETRY 
MALDI-TOF MS was performed using a Bruker Ultraflex III MALDI-TOF 
instrument operating in the positive ion, delayed-extraction mode; linear mode 
with ‘ion source 1’ at 25.00 kV, ‘ion source 2’ at 23.50 kV, lens at 6.00 kV, 50 ns 
delayed extraction, deflection signal suppression up to m/z 3000, and 1 GS/s 
sample rate.  Single measurements were acquired, per individual, using twenty 
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thousand laser-shots signal averaged to ensure good ion counting statistics.  
Spectra were externally calibrated with a mixture of 4 proteins, supplied by 
Bruker (Cat. No. 208241), ranging from m/z 5734.52 (Insulin [M+H]+) to m/z 
12,360.97 (Cytochrome C [M+H]+). 
 
DATA PROCESSING 
Individual mass spectra were baseline subtracted (Tophat algorithm) and 
smoothed (SavitzkyGolay algorithm; width = 0.2 m/z; cycles = 1) prior to peak 
integration using Bruker Daltonics flexAnalysis 3.0.  Peaks representing intact 
RANTES and RANTES variants were integrated (using Intrinsic Bioprobes Inc. 
Zebra 1.0) and tabulated in a spreadsheet for determination of relative percent 
abundances. 
 
DUAL EXTRACTION 
RANTES was extracted as described above followed by elution into a new sample 
reservoir.  This new reservoir was then extracted as if it were a plasma sample 
itself, generating a high purity sample with minimal non-specific protein binding 
and an exceptionally clean MALDI-TOF-MS spectrum of RANTES. The dual 
extraction was performed by extracting 20 tips using the normal sample 
preparation (with the exception of using 1 mL plasma and 500 µL detergent 
solution per sample) followed by MSIA tip elution with 7 µL of 33% (v/v) 
acetonitrile and 0.45% (v/v) TFA into an eppendorf tube containing 1 mL HBS-N 
(0.01M HEPES and 0.15M NaCl) and 10 µL of 3.9 g/L prealbumin antibody 
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(DAKO). The antibody was used as a carrier protein. This enriched sample was 
subsequently extracted using a new anti-RANTES affinity pipette and eluted 
using the same methodology as previously described. The process was repeated 
exactly using anti-human insulin antibody immobilized tips to serve as a negative 
control. 
 
RESULTS AND DISCUSSION 
Figure 14 shows a MSIA spectrum that is qualitatively representative of those 
obtained for the individuals investigated in this study (note: spectrum is a resized 
version of that seen in Panel B of Figure 15). Along with intact RANTES, the 
following variants were identified: two N-terminally truncated forms (maroon; II 
and III), one C-terminally truncated form (pink; V), seven C- and N-terminally 
truncated forms (blue; IV, VI, VIII, and X-XIII), glycated forms representing 
intact and [3-68] (purple; VIII and XIV), oxidized forms (+16 m/z, unlabeled), 
and four glycosylated forms  (green; XVI-XIX) (see Figure 14 and Table 4), for 
a total of at least 19 variants. After fine-tuning to ensure that all MS signals were 
specific to RANTES via a dual extraction (described below), the ions represented 
in Fig. 14 were tentatively mass mapped.  Most of these peaks were found in the 
majority of the samples. With regards to specificity of peak assignments, this type 
of technique may be viewed as analogous to an ultra-high resolution western blot 
that is performed hundreds of times with consistent results.  Notably, peaks I-XIX 
were not observed in control experiments using blank tips (no antibody 
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immobilized), anti-human C-peptide MSIA tips (single extraction), and anti-
human Insulin MSIA tips (single and dual extraction).   
 
 
 
 
Figure 14: Mass spectrum resulting from the targeted top-down analysis of 
RANTES. Indicated are signals from the ~19 major protein isoforms. Isoforms 
fall into six categories: C- and N-terminal truncation, N-terminal truncation 
only, C-terminal truncation only, multiple truncation possibilities (due to 
identical masses), glycosylation, and glycation. Table 1 lists the identities of 
each variant. A1 and A2 denote signals that appeared in negative control 
experiments and therefore may not be related to RANTES (8215.4 m/z and 
8603.5 m/z). B1 and B2 denote signals that may be related to RANTES but are 
unknown (8404.28 m/z and 8421.33 m/z). 
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To ensure accurate mass mapping assignments, the development of a 
secondary extraction process (dual extraction) was designed to support the 
removal of nonspecifically bound proteins and to create an exemplar full-scan 
spectral view of endogenous RANTES microheterogeneity in humans. Typically, 
one MSIA affinity pipette is used to extract a protein from a single plasma 
sample, which is then rinsed and immediately eluted. Here we eluted many 
affinity pipettes from pooled human plasma into a single buffered solution to 
create a sample with much lower non-specific protein concentrations and 
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significantly higher RANTES concentration. This consequently created a vastly 
cleaner MSIA MALDI-TOF-MS spectrum with amplified signals corresponding 
to the weakest endogenous RANTES species present within humans (see Figure 
15).   
Relative percent abundance (RPA) values of isoforms can be obtained after 
integrating all mass spectral peak areas (previously determined by a verified 
protein variant map, e.g. Figure 14), followed by dividing the peak area of each 
isoform by the summed areas of all isoforms and finally multiplying by one 
hundred. To test the reproducibility of this form of semi-quantification, a single 
sample was run 96 times (i.e. 96 MSIA tips extracted RANTES from same 
individual from 96 samples). In this test, RANTES variants [1-68], [3-68], [4-68], 
and [4-66] had RPA values ± standard deviations of 77.82 ± 0.53, 20.3 ± 0.49, 
1.26 ± 0.07, and 0.62 ± 0.05. The range for these variants were observed to be 
77.08 – 79.60 %, 18.67 – 20.97%, 1.08 – 1.43 %, and 0.51 – 0.76% respectively. 
After establishing a map of RANTES heterogeneity, individual classes of 
posttranslational modifications were scrutinized in more detail as follows. 
TRUNCATION 
RANTES was found consistently in a multitude of N- and C- terminally truncated 
forms (ten individual truncated isoforms were identified). The two previously 
known truncated variants, [3-68] (II) and [4-68] (III), are generated by two 
separate regulatory enzymes: DPP-IV and Cathepsin G (100, 101).   
    
72 
 
 
 
 
Figure 15: Dual extraction methodology. Mass spectra resulting from the targeted top-down analysis of 
RANTES from a healthy pooled plasma sample using a standard single MSIA extraction (I) and also after 
a dual MSIA extraction (II). Indicated are signals from the major nonspecific binding proteins 
(Apolipoprotein C11, Apolipoprotein C32, and unknown*). 
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RANTES, as with most chemokines, contains its receptor binding motif at the N-
terminus, thus if truncation proceeds, modified chemotactic activity ensues. 
Therefore, the information content is twofold within such a multiplexed assay: 
indirectly, the enzymatic activity/expression and directly, the relative abundance 
of inactive and active protein variants. In this context, this is in the form of DPP-
IV and Cathespsin G activity from the abundance of [3-68] and [4-68] and each 
individual’s relative ability to induce and/or block signal transduction on target 
receptors (e.g. full length RANTES versus DPP-IV cleaved RANTES). As for the 
other eight alternate truncated forms of RANTES found here, the enzymatic 
activity they indirectly represent remains unknown. A decade ago, Proost et al 
reported on two related C-C chemokines, MCP-1 and MCP-2, and the discovery 
that they exist in several N- and/or C-terminally truncated forms with 
corresponding modified activity (111).  Notably, they observed that N- truncated 
forms were almost completely devoid of activity but C-terminus-only truncated 
forms retained full activity. Furthermore, they observed a particular N- truncated 
form of MCP-2 to act as a natural inhibitor for MCP-2, MCP-1, and RANTES in 
regards to chemotactic activity. Proost also found an analogous case with 
RANTES [3-68] whereby they observed the variant to also act as a natural 
inhibitor against full length RANTES and as an effective antagonist of HIV entry 
into mononuclear cells (112).  We expect these N-terminal truncated variants to 
be devoid of activity with increasing lack of receptor specificity the further the 
variant is truncated inward. Conversely, we expect the C-terminal truncations to 
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have little effect on biological activity. This may be superfluous in this case, 
however, because most of the C-truncated variants are also N-truncated. A case-
in-point example regarding the imperative of acknowledging all truncated 
isoforms of a protein comes from the calcium regulatory protein Parathyroid 
Hormone (PTH). PTH exists in several embodiments including N- and/or C- 
truncations. PTH binds to two separate receptors, the classical receptor is specific 
for the amino terminus and an as-of-yet uncloned receptor on the carboxyl 
terminus, the two exerting opposite biological effects in modulating calcium 
concentrations (113, 114). Interestingly, PTH microheterogeneity had been 
studied for almost half a century but the possibility of a C-terminal receptor 
binding domain was assumed to not exist until very recently. We recently 
produced a multiplexed assay than can simultaneously distinguish between these 
active forms (26). Thus, it seems logical that additional assays stand to profit from 
the ability to unambiguously identify, in a multiplexed manner, an entire full 
length protein form. Conversely, as with most “biased” quantification proteomic 
approaches whereby only one or two surrogate peptides (resulting from a tryptic 
digest) are monitored to represent an entire set of protein variants as they exist 
endogenously, the degree of protein heterogeneity presented here would have 
been disguised and unacknowledged.  This would have been true for all truncated 
forms if the surrogate peptide were chosen from a mid-region. Even if a surrogate 
peptide were chosen from a terminal region (e.g. to represent 3-68), the assay 
would still be blind to C-terminal truncation and the possibility of discovering 
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more variants. The MSIA analytical approach allows for the continual analysis of 
all of these variants. 
 
 
 
 
 
 
Figure 16: Mass spectra from a T2D individual and a non-T2D 
individual. Table 1 lists the identities of the individual variants. Note the 
correlation between the ratio of [1-68] (I) and [3-68] (II) to the ratio of XXII 
(I) to XIX (II) (both glycosylated with Deoxyhex1HexNAc3Hex1). Also note 
the increase in glycation observed in the T2D sample.  
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GLYCOSYLATION AND GLYCATION  
We mass mapped the presence of at least four putative O-linked glycosylated 
variants that appear to exist on both intact and truncated forms of RANTES 
(observable only on [1-68] and [3-68]; more were not detected corresponding to 
the other variants likely due to their already low relative abundance). A ladder 
like structure was observed reaching its largest potential at a mass of 8926.9 Da 
representing intact RANTES with Deoxyhex1HexNAc3Hex2  (see Figure 14 and 
Table 4).  Importantly, the ratio of O-glycosylated (Deoxyhex1HexNAc3Hex1) 
intact (XVIII) to O-glycosylated (Deoxyhex1HexNAc3Hex1)  [3-68] (XVI) was 
found to be conserved relative to the ratio of intact (I) and [3-68] (II) among 
essentially all samples in the population study, providing further verification of 
the mass mapping assignments (Figure 16). About two decades ago, Kameyoshi 
et al discovered a putative RANTES variant that possessed the same N-terminal 
sequence as intact RANTES yet had an increase in mass of approximately 500 
mass units (full length intact protein was detected at 8355 ± 10 m/z). It was 
assumed to be an O-glycosylated variant due to the absence of edman degradation 
sequence information at a hypothesized dual serine O-glycosylation site (at 
residues 4 and 5). Interestingly, they observed that this variant retained similar 
eosinophil (Eo) chemotactic activity relative to the native form (102). This 
putative variant was not detected in this study. A few years later, Proost et al (in 
the same study mentioned previously (111)) found O-linked glycosylated variants 
of MCP-1 which had a 2-3 fold decrease in chemotactic function on monocytes 
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and human acute monocytic leukemia cell lines (THP-1) relative to intact MCP-1. 
Because of the structural relatedness between RANTES and MCP-1, it remains 
quite possible for RANTES O-linked glycosylation variants to have modified 
activity as well. Regardless, it is essential to be aware of RANTES in all of its 
structural embodiments.  
The glycated signatures of [1-68] and [3-68] were detected in the majority of 
samples. Glycation is common among plasma proteins.  To date, however, there 
do not appear to be any previous reports of RANTES glycation. As we previously 
demonstrated with Vitamin D binding protein (DBP) (21), significant population 
differences in DBP glycation levels between healthy, T2D, CVD, and Cancer 
were found to be common. Predictably, there is a markedly high increase in 
glycation in the Diabetic and Cancer samples studied here. Figure 16 displays the 
RANTES spectrum of a non-T2D (CVD) patient compared to that of a T2D 
patient. A glycation peak is observed in the T2D spectrum labeled XIV (I) but this 
peak is absent in the non-T2D spectrum. Several population trends such as this 
were encountered (Figures 17-20). 
POPULATION STUDY 
Figures 17-20 represent a population of ~250 individuals in different states of 
health and the diversity of RANTES found therein. The relative abundance for 
several distinct categories of RANTES heterogeneity is presented. Significant 
RPA differences were observed between all disease cohorts. The subsequent 
figures compare the relative abundance of [1-68] and [3-68] (Figure 17), 
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Oxidation (Figure 18), Glycation (Figure 19), and [4-66], [3-66], [3-67], and [1-
66] (Figure 20) across all of the disease states. Obvious variation in RANTES 
profiles begin to emerge in this larger context .   
 
For example, in Figure 17 a large increase in the RPA of [1-68] and a large 
decrease in RPA of [3-68] is observed in the majority of the diseased individuals 
relative to the healthy controls. In Figure 19 glycation increases significantly in 
the diseased cohorts with the T2D indivduals unsurprinsgly exhibiting the highest 
Figure 17: Stacked bar plot population data for mixed cohort of about 250 
individuals: [1-68] and [3-68]. Healthy, T2D, CHF (with or without T2D and/or 
MI), and Cancer [1-68] averages were 7.54%, 48.31%, 44.99%, and 43.12%. 
T2D, CHF (with or without T2D and/or MI), and Cancer [1-68] statistically 
significant from the healthy cohort at P < 0.001. Healthy, T2D, CHF (with or 
without T2D and/or hMI), and Cancer [3-68] averages were 78.15%, 33.66%, 
44.99%, and 43.12%. Healthy [3-68] statistically significant from the T2D, CHF 
(with or without T2D and/or hMI), and Cancer cohort at P < 0.001.  
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relative abundace with a average value and range of 1.84 ± 0.84% and 0.68 – 
4.06% compared to the healthy cohort value of 0.43 ± 0.35% and range of 0.05 – 
2.55%  (note: the glycation calcuation comes from adding the glycated [1-68] and 
[3-68] together).  
 
 
 
In Figure 18 a markedly higher RPA of oxidized RANTES is observed in the 
diseased individuals, with the highest increase observed in those with a history of 
myocardial infarction (average value and range of 9.65 ± 7.16% and 0.27 – 
30.86% compared to the healthy cohort value of 1.42 ± 0.69% and 0.17 – 3.63%).  
Figure 18: Population data for mixed cohort of about 250 individuals: 
oxidized RANTES. Averages of oxidized RANTES in healthy, T2D, CHF and 
MI, and Cancer were 1.23%, 6.12%, 9.65%, and 2.24%. Healthy oxidized 
RANTES was statistically significant from the T2D and hMI cohorts at P < 
0.001 and statistically significant from the cancer cohort at P = 0.0013. 
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Finally,  the differences in the relative percent adundances of the lowest level 
truncated variants is presented in Figure 20 with micro differences observed 
between most disease states including the abnormal higher relative adundance of 
[1-66] in the CHF and hMI individuals with an average value and range of 3.05 ± 
7.54% and 0.02 – 36.67% compared to the healthy cohort value of 1.07 ± 0.58% 
and 0.10 – 4.26%.   
Figure 19: Population data for mixed cohort of about 250 individuals: 
glycated RANTES. Averages of glycated RANTES in healthy, T2D, and CHF 
(with or without T2D and MI) were 0.55%, 1.84%, and 1.36%. Healthy glycated 
RANTES was statistically significant from the T2D and CHF (with or without 
T2D and MI) cohort at P < 0.001.  
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Recognizing heterogeneity in this context of multiple diseases presents a unique 
prospect for diagnosing more than one disease, using independent variant 
markers, from a single protein analysis. It is only after looking at protein 
phenotypes (e.g. concentration and posttranslational modifications) in the context 
of populations when deviations in protein multiplicity, including changes in 
population frequency and relative abundance, become clear and thus biomedically 
applicable (21, 31). 
Figure 20: Stacked bar plot population data for mixed cohort of about 250 
individuals: low level isoforms. Relative abundance of some of the lowest level 
RANTES isoforms: [4-66], [3-66], [3-67], and [1-66] are shown. 
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Notably, due to the ex vivo activity of enzymes in plasma (confirmed from our 
laboratory by observing intact to be processed into [3-68]) future population 
studies may be designed with the use of collection tubes containing enzyme 
inhibitors. This will guarantee an accurate readout of bioactive (and inactive) 
RANTES isoforms at the time of collection, which will also be beneficial to 
establishing inter-laboratory standardizations. Regardless, the results illustrate the 
necessity to acknowledge RANTES diversity and optimistically suggest it may 
hold multipurpose clinical utility. 
In the span of two decades studies have quickly taken the comprehension of 
RANTES from a single gene product found in T-cells to a molecule that appears 
to be related with several diseases, expressed in a range of tissues, and acutely 
regulated via truncation by specific enzymes. This report adds to this the body of 
work by introducing over sixteen new forms of the molecule apparent in human 
plasma in the context of disease populations. The structural variety RANTES 
exhibits in different disease states should influence the design of future 
quantitative clinical assays (choice of variant to monitor, internal standard, etc). 
The population diversity explored here strongly suggests RANTES variants 
should be monitored, independent from one another, to assess RANTES 
chemokine function and regulation accurately in the context of disease. 
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Chapter 7 
A MASS SPECTROMETRIC IMMUNOASSAY FOR KIDNEY DISEASE AND 
RELATED DISORDERS 
It is estimated that 11.5% of adults 20 years and older in the United States 
(approximately 23 million individuals) have physiological indications of having 
chronic kidney disease (CKD) (115).  Alarmingly, there were 87,812 deaths in 
2007 for all patients undergoing treatment for end state renal disease (ESRD) 
(116). Furthermore, ESRD resulted in $35.32 billion dollars in public and private 
spending in the United States in the year 2007 (116). Due to its widespread 
prevalence in the population and the corresponding economic burden, new 
targeted proteomic solutions that help detect, monitor, and assist in treating 
kidney disease may have substantial clinical utility.  
Chronic kidney disease and related complications arise from abnormalities in 
the metabolism of calcium, phosphorous, and magnesium (117). Regulation of 
these minerals is accomplished principally through interactions between three 
major organs: the intestine, bone, and kidney. These organs communicate via two 
chief hormones: parathyroid hormone (PTH) and vitamin D. PTH is secreted from 
the chief cells of the parathyroid gland and is activated via a negative feedback 
loop when plasma Ca2+ levels drop. PTH restores calcium homeostasis in healthy 
individuals by increasing bone mineral dissolution (which releases stored calcium 
and magnesium from the bone), increasing calcium and magnesium renal 
reabsorption, and indirectly by triggering 1,25(OH)2D (calcitriol) synthesis, the 
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active form of Vitamin D, which augments gastrointestinal absorption of calcium 
and phosphorous (117, 118).  
PTH is synthesized in the parathyroid glands via a two-step conversion of 
prepro-PTH (115 amino acids) to pro-PTH (90 amino acids), and finally to the 
native 84 amino acid form: PTH (1-84). Individuals with CKD typically have 
elevated PTH plasmatic concentrations due to several factors including phosphate 
retention, hypocalcemia, and calcitriol deficiency, with prolonged periods of PTH 
secretion leading to the condition known as secondary hyperparathyroidism (119, 
120). As a consequence of extended periods of elevated bioactive PTH levels and 
disrupted mineral metabolism, individuals are threatened with bone abnormalities, 
calcification of the cardiovascular system, and increased mortality. PTH has a 
half-life of approximately 4 minutes (121) and is quickly degraded via uptake and 
proteolytic processing within the Hepatic Kupffer cells, followed by release back 
into circulation (122). This action produces an abundance of shortened, C-
terminal PTH variants, which themselves have considerably longer half-lives due 
to their clearance exclusively by glomerular filtration (i.e. kidney clearance). It is 
therefore of paramount importance for assays to accurately measure the bioactive 
form of PTH distinct from C-terminal PTH variants for effective detection and 
management of PTH related diseases (e.g. CKD, hyperparathyroidism, etc).  
Indeed, clinicians for the past 50 years have been determined to realize the 
objective of unambiguous bioactive PTH detection. Three generations of PTH 
assays have served clinicians in interpreting bioactive PTH levels, with varying 
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degrees of success. The motivation for subsequent generations of PTH assays has 
been due to two principle discoveries: PTH exerts its effects if its N-terminus is 
intact (i.e. the first 34 amino acids (123)) and 80-95% of circulating PTH is N-
terminally truncated (114, 124). This “paradox” has motivated researchers to 
uncover the truth behind PTH. First generation PTH assays (circa 1971) were 
radioimmunoassays with antibody epitopes located towards the c-terminus of the 
molecule (125, 126). As PTH exists largely as N-terminally truncated variants and 
is thus inactive, these assays were supplanted by later generation assays due to the 
large degree of cross-reactivity. Second generation assays were developed as a 
reaction to interference and are called Intact (I)-PTH assays. These sandwich 
assays were built with capture antibodies specific for PTH (39-84) and detection 
antibodies specific for PTH (1-34), with the later having epitopes typically 
between 13-34 (127). Although these assays had a substantial impact on the 
community and are still widely used, these assays were later found to cross-react 
with the highly potent, opposite acting forms deemed non-(1-84) PTH fragments 
(e.g. PTH (7-84)). These fragments can comprise up to 45% of immunoreactive 
PTH in renal failure individuals and 20% in health individuals (128).  As such, at 
the turn of the century third generation assays began to emerge that had detection 
epitopes in the 1-4 region (129). Despite these assays yielding a solution that 
provides a high-degree of certainty in detecting intact N-terminus PTH, these 
assays were found to cross-react with PTH molecules containing a theoretical 
phosphate group (114), and, if PTH exists in other unanticipated forms such as C-
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terminal truncated forms, cross-reactivity caused by such forms and the 
implications remain questionable. As a result, innovative diagnostic approaches 
that provide a “fourth generation PTH assay” solution may engender clinical 
utility if able to solve the unmet needs of previous generations of assays. Such an 
assay might provide unambiguous detection of bioactive PTH (i.e. intact N-
terminus PTH) as well as multiplexed detection capabilities of additional 
modified forms of PTH within the framework of the recently acknowledged dual 
nature of the PTH molecule (114). Indeed, this emerging biological model views 
PTH as a molecule that depending upon its proteolytical processing within the 
parathyroid glands and/or peripheral tissues, can exert opposing effects on 
calcemic homeostasis via two distinct antagonistic receptors which bind to the 
opposite ends of the molecule -- the N-terminus and C-terminus (114, 130-132).  
As such, assays that can accurately detect and monitor PTH in the context of the 
newfound dual nature of PTH may have clinical utility. 
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PARATHYROID HORMONE MICROHETEROGENEITY IN RENAL 
FAILURE POPULATIONS  
Parathyroid hormone (PTH) has remained an elusive protein despite decades of 
research aimed at uncovering structural variants that exist within individuals. An 
emerging paradigm regarding PTH has begun to reconcile the complexity 
surrounding PTH microheterogeneity by acknowledging that PTH binds to two 
separate receptors (114). The PTH/PTHrP type I receptor exerts the classical 
biological effects of PTH by binding to the intact n-terminal domain of PTH 
(intact PTH can account for as little as 5% total circulating PTH). The second 
receptor binds C-PTH fragments, which correspondingly binds to the intact c-
terminal domain (e.g. PTH34-84 binds to this receptor). These receptors exert 
opposing biological effects in regulating Ca2+ concentration. Regarding the origin 
of C-PTH fragments, C-PTH is released from the parathyroid glands in a Ca2+ 
dependent manner and may also be produced in the liver Kuppfer cells via the 
conversion of circulating PTH (1-84) in C-PTH (133). The general consensus is 
that circulating PTH largely exists as numerous structural forms but the precise 
structural compositions are unknown and likely vary from individual to 
individual. 
A limitation of previous generations of PTH assays that are built using 
ELISAs and related technologies is that they rely on detection based solely on 
antibody-PTH interactions. In this mode, the detected species cannot be directly 
known with 100% certainty. The detection is “interpreted” via a chemical reaction 
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or fluoresce signal rather than an unambiguous “molecule specific” method such 
as that may be yielded with a mass spectrometer. Nonetheless, third generations 
assays such as the CAP (cyclase-activating PTH) assay from Scantibodies 
Laboratory and the Bio-Intact PTH assay from Nichols Institute Diagnostics have 
excellent interday CVs ranging from 3.4-8.3% (8.3% at 31ng/L) and 2.7-3.7%  
(2.7% at 20.8ng/L), respectively, and have detection capabilities at relevant 
physiological concentrations (134). Given that PTH is a molecule that is 
correlated to several conditions such hyper/hypoparathyroidism, 
hyper/hypocalcemia, CKD, and parathyroid adenoma, and exists largely as 
distinct isoforms in circulation, identification of disease specific profiles of PTH 
presentation in blood may have impact in the clinical community. To this end, this 
study focuses on the use of mass spectrometric immunoassay (MSIA) (25) to map 
structural differences of PTH found in ESRD relative to healthy individuals as a 
beginning point in establishing distinct PTH disease profiles. Such profiles will 
help facilitate the successful translation to a clinically applied mass-spectrometric 
PTH platform.  
Of note, besides offering an introduction to the PTH work I personally 
conducted, this chapter is intended to describe which unique attributes and 
insights I provided for the subsequent chapter  (previously published (26)) 
wherein I was a co-author and had a significant contribution. 
 
    89 
EXPERIMENTAL 
This experimental section closely follows the protocol employed in the subsequent 
chapter (26). 
REAGENTS 
Goat polyclonal Anti PTH39-84 antibody was purchased from Immutopics 
International (San Clemente, CA). Recombinant human PTH (rhPTH) was 
obtained from Bachem (Torrance, CA). Premixed MES-buffered saline powder 
packets were from Pierce (Rockford, IL). Extraction of PTH from plasma was 
carried out with proprietary MSIA pipette tips (MSIA-Tips) from Intrinsic 
Bioprobes (Tempe, AZ) derivatized with the PTH antibodies via 1,1’ 
Carbonyldiimidazole (CDI) chemistry as described below. Premade 10X 0.1M 
Hepes-buffered saline buffer (HBS-N) with 30 mM EDTA and 0.2% (v/v) 
surfactant P20 (HBS-EP) were purchased from BIACORE (Piscataway, NJ). 
Synthetic heavy labeled peptides were obtained from Thermofisher (Ulm, 
Germany). All other chemicals were obtained from Sigma-Aldrich (St. Louis, 
MO).  
 
SAMPLES 
All samples used in this study were acquired under an Institutional Review Board 
(IRB) approved protocol and Informed Consent. Twenty four serum samples 
representing twelve individuals diagnosed with either sever renal impairment or 
end-stage renal disease (10 males and 2 females; mean age 66.7) and twelve 
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healthy individuals (10 males and 2 females; mean age 65) were used in the study. 
The renal failure samples represented 3 Hispanics, 2 Asians, 2 African 
Americans, and 6 Caucasians. Information on the ethnicities of the healthy 
samples was not available.  
 
SAMPLE PREPARATION AND IMMUNOCAPTURE 
MSIA-Tips were prepared by Intrinsic Bioprobes as previously described (22, 23, 
25, 135). Prior to analysis samples were thawed to 25 oC using a water bath and 
one mL of plasma was diluted with 750 µL HBS-EP buffer to result in a total 
analytical volume of 1.75 mL. PTH was then extracted with the aid of a Beckman 
Multimek 96 pipetting robot by repeatedly (1,500 repetitions) drawing and 
expelling (back into the analytical volume) 125 µL aliquots of the analytical 
volume through the antibody prelinked MSIA-Tip. After extraction, the pipettes 
were rinsed using HBS-EP, H2O, 3:1 ratio of ammonium acetate/acetonitrile, and 
again with H2O (in this order, each rinse = 15 repetitions of 150 µL), after which 
PTH was immediately eluted for detection with MALDI-TOF-MS. 
 
MALDI-TOF MASS SPECTROMETRY 
Samples were prepared for MALDI-TOF MS by drawing 4 µL of MALDI matrix 
solution (saturated aqueous solution of sinapic acid, in 33% (v/v) acetonitrile, 
0.4% (v/v) trifluoroacetic acid, TFA) into the pipette and depositing onto a 
MALDI-TOF-MS target (136). MALDI-TOF-MS was performed using a Bruker 
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Ultraflex MALDI-TOF instrument operating in the positive ion, delayed-
extraction mode; reflector engaged with ‘ion source 1’ at 25.00 kV, ‘ion source 2’ 
at 21.90 kV, lens at 9.50 kV, ‘reflector’ at 26.30 kV, ‘reflector 2’ at 13.80, 340 ns 
delayed extraction, deflection signal suppression up to m/z 4000, and 2 GS/s 
sample rate. Ten thousand laser-shots were signal averaged for each mass 
spectrum using a laser repetition rate of 100 Hz.  Spectra were externally 
calibrated with a mixture of 4 proteins supplied by Bruker (Cat. No. 208241) 
ranging in average m/z from 5734.52 (Insulin [M+H]+) to 12,360.97 (Cytochrome 
C [M+H]+). 
 
RESULTS AND DISCUSSION 
Figure 21 (bottom panel), shows two qualitatively representative mass spectra 
overlaid to depict the healthy and renal failure individuals in this study. The top 
panel displays the “PTH variant map” created from the PTH diversity 
encountered within this study (variants correspond to signals observed in the 
bottom panel). PTH was found to exist in multiple variations within all of the 
samples. These modified forms may be conceptually grouped into three 
categories: positive acting forms (i.e. classical biological effects of intact PTH), 
negative acting forms (i.e. opposing effects relative to intact; i.e. C-PTH 
fragments), and assumed inactive forms. The only form of PTH that acts as a 
classically active form, at least detected by this assay, is intact PTH. However, it’s 
possible there may be endogenous PTH fragments that have an intact N-terminal 
    92 
domain. PTH exerts its function on bone and kidney by binding to the 
PTH/PTHrP receptor and by likewise initiating the protein kinase A and C 
pathways in respective tissues (114, 137). Intact PTH was observed in all of the 
renal failure samples and in only two of the twelve healthy samples. These results 
are consistent with the pathophysiology of kidney disease whereby due to the 
decreased levels of calcium in serum, excess PTH is secreted by the parathyroid 
glands in attempt to increase the calcium levels.  C-PTH fragments were also 
observed in higher S/N and in much higher frequencies relative to the healthy 
controls. This is also consistent with other studies finding that C-PTH fragments 
(albeit the C-PTH identities were unknown) represented more than 95% of the 
total hormone in circulation compared to just 80% in healthy individuals (via a 
two-site immunometric assay) (114, 128). Signals were considered relevant if S/N 
> 3. C-PTH fragments observed in populations included: PTH (28-84), PTH (34-
84), PTH (37-84), PTH (38-84), PTH (45-84), and PTH (48-84) (PTH 28-84 and 
PTH 48-84 were previously unreported). The frequencies of these fragments in 
the renal failure population were consistently found in at least in 8 out of 12 
individuals. In the healthy cohort, these frequencies were decreased and were 
consistently found in less than 8 of out 12 individuals. The third groups of PTH 
molecules detected were previously unreported C-terminally truncated C-PTH 
fragments, which are assumed to be inactive (although this remains to be proven).  
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Figure 21: PTH variant map. Top panel: A.  list of all the N-terminally 
truncated PTH variants identified previously by others that were detected in this 
study B. Variants discovered and added to the map during this study using full-
scan MSIA (MALDI-TOF-MS). All variants depicted in (A) and (B) were 
observed in the majority of clinical samples under investigation. (MALDI-TOF-
MS) spectra representative of the 12 renal failure samples (blue) and the 12 
healthy controls (red).  The following species, as seen labeled in the figure, were 
consistently found at higher frequency relative abundance in the renal failure 
cohort (m/z observed; calculated): PTH1-84 (9426.03; 9425.71), PTH28-84 
(6179.61; 6179.91), PTH34-84 (5472.91; 5473.16), PTH37-84 (5155.71; 
5155.77), PTH38-84 (5051.92; 5051.61), PTH34-77 (4715.98; 4716.26), PTH37-
77 (4397.71; 4398.87), PTH45-84 (4379.65; 4379.82), PTH38-77 (4285.57; 
4285.71) and PTH48-84 (4136.42; 4136.60). 
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Others had already shown that C-truncated PTH molecules exist but their specific 
identities were not known (113); this data thus serves to begin establishing the 
identities of these molecules. A conserved truncation site at residue 77 was also 
observed in the molecules. These fragments included: PTH (34-77), PTH (37-77), 
and PTH (38-77). These findings are intriguing because they may represent the 
aftermath of a secondary regulatory mechanism in inactivating negatively acting 
C-PTH fragments. These were found in the renal failure samples at a frequency of 
≥ 8 out of 12 individuals and  ≤  5 out of 12 individuals within the healthy cohort. 
Notably, many more truncated forms of PTH were mass mapped to PTH 
isoforms, but due to their relative low population frequencies, they have been 
omitted from Figure 21.  
Table 5 shows the populational frequencies of all signals that have been mass 
mapped to PTH variants. This addresses the question of the number of samples 
(of the total) in which a particular protein variant was observed. When these three 
classes of PTH variants are taken into consideration regarding the new dual 
receptor paradigm (PTH/PTHrP type 1 receptor and the C-PTH receptor), an 
insight into an individual’s unique Ca2+ metabolism and (indirectly) bone turnover 
profile is presented from within a single PTH MSIA MALDI-TOF-MS spectrum 
respective to the parathyroid gland’s response.   
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ROC (receiver operating characteristic) curve analysis can be a useful tool in 
diagnostics to display the efficacy of a particular test in discriminating diseased 
individuals from healthy individuals (138). Many of the PTH isoforms explored 
here produced very high ROCAUC values via an analysis of variant signal intensity 
(area under the ROC curve; this indicates the true positive rate and true negative 
rate with a value of 1 equaling perfect discrimination). For the most abundant ions 
(PTH (34-84), PTH (37-84), and PTH (38-84)) ROCAUC values were ≥ 0.98, 
indicating the variants were capable in differentiating renal failure samples from 
healthy samples (e.g. Figure 22). This is encouraging due to renal failure being 
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linked to stage 5 of chronic kidney disease. Likewise, a spectrum in the form of 
elevating PTH isoforms is ultimately desired if one wants to monitor (and predict) 
the progression of CKD from stages 1-5. A second type of discrimination 
emerged from comparing the ratio of C-PTH to inactive forms (the two specific 
variants used here are PTH 34-84 / PTH 38-77). The population ratio average for 
the renal failure cohort was found to be 1.54 ± 0.9 compared to a very narrow 
distribution of just 0.31 ± 0.16 for the healthy cohort. These results are interesting 
because they suggest inactive fragments may also be regulated differently 
between disease states (along with C-PTH fragments). Figure 22 presents a ROC 
curve demonstrating the diagnostic efficacy of PTH (34-84).  
 
 
Figure 22: ROC curve for PTH (34-84). On the left: averaged spectra of the two 
cohorts for three PTH variants (each red x represents a renal failure individual and 
their respective signal intensity; each green o represents a healthy individual and 
their respective signal intensity). PTH variants PTH34-84 (5472.91; 5473.16), 
PTH37-84 (5155.71; 5155.77), PTH38-84 (5051.92; 5051.61) are shown 
(observered, theoretical m/z). On the right: an ROC curve for the PTH variant 34-
84. This ROC curve yeilds 100% sensitivity (no false negatives) and 100% 
specificity (no false positives), and thus it’s ROC(AUC) value of 1.0.  
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Described here is a high throughput, multiplexed mass spectrometric 
immunoassay (MSIA) that in a single analysis detects PTH1-84 (wild-type), C-
PTH variants (e.g. PTH (34-84)), and previously unreported C-terminally 
truncated variants (e.g. PTH (38-77)) using MALDI-TOF-MS. In application, the 
assay was successful in stratifying renal failure from matched healthy controls 
(with ROCAUC > 0.90 for individual variants and in multiplexed mode). The 
protein diversity explored here adds to the growing awareness and interest in 
studying protein heterogeneity in the general population. This information in turn 
serves two functions, it can help explain heterogeneity that may have interfered 
with conventional PTH assays (i.e. biological noise) and it may also, as 
demonstrated here, include determinant data linked to specific diseases (e.g. 
chronic kidney disease). Accordingly, from a single PTH MSIA spectrum it may 
be possible to observe an individual’s unique calcium metabolism and bone 
turnover profile. Future large scale population studies devoted towards more 
comprehensive screenings of PTH variants specific for disease will have 
important clinical utility in the understanding and diagnosis of endocrine and 
bone diseases. Lastly, the work presented here serves as a starting template to 
create a next-generation PTH quantitative assay that simultaneously detects 
bioactive PTH as well as disease-specific PTH isoforms. 
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Chapter 8 
SELECTED REACTION MONITORING–MASS SPECTROMETRIC 
IMMUNOASSAY RESPONSIVE TO PARATHYROID HORMONE AND 
RELATED VARIANTS 
Parathyroid hormone is produced in the parathyroid glands through the 2-step 
conversion of prepro-PTH (115 amino acids) to pro-PTH (90 amino acids) to the 
84 amino acid peptide (PTH1-84). The hormone is secreted into the circulatory 
system to produce basal (healthy) concentrations of approximately 15–65 ng/L 
(139), and is assayed to assist in the diagnosis of hypo/hyperparathyroidism and 
hypercalcemia and in monitoring for renal osteodystrophy in patients with end-
stage renal failure (139-141). Conventional PTH assays typically rely on 2-
antibody recognition systems coupled to a variety of detection modalities (142-
144). Notably, the most specific assays are able to differentiate between different 
truncated forms of PTH and are referred to as second- and third-generation PTH 
assays (145, 146).  
Key to the application of these later-generation assays is the ability to 
selectively monitor various PTH forms of known biological consequence. In 
particular, 2 variants, full-length PTH1– 84 and PTH missing the 6 N-terminal 
amino acids (PTH7– 84), are the subject of increased clinical investigation and 
potential diagnostic capability. Because of the inability of existing assays to detect 
microheterogeneity (21), these variants were historically considered as a single 
PTH value (i.e., the first-generation assays) (145). The classification of each 
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variant as its own molecular entity and the analysis and study of each 
independently suggest an antagonistic relationship between the 2 different forms 
in regard to calcium homeostasis (147). In fact, there is mounting clinical 
evidence that the ratio between PTH1– 84 and PTH7– 84 may be used to 
differentiate between hyper- parathyroid bone turnover and adynamic bone 
disease (148-150). 
The PTH (1-84) to PTH (7-84) paradigm is a recent example of the biological 
and clinical utility of microheterogeneity within the PTH protein. Indeed, other 
PTH variants were defined as far back as approximately 40 years ago. Perhaps the 
most mature of these, PTH (1-34), has been identified as an in vivo variant that 
exhibits biochemical activity comparable to the full-length protein. Consequently, 
PTH (1-34) is a classic example of a peptide-based bioactive variant that has 
transitioned through drug development to the point of US Food and Drug 
Administration clearance for the treatment of osteoporosis [rPTH1–34 
(teriparatide)] (151-153). Collectively the routine monitoring of these clinically 
relevant PTH variants – PTH (1-84), PTH (7-84), and PTH (1-34) -- is achieved 
through 3 separate, highly specific immunometric assays. However, there are 
indications that even greater microheterogeneity exists within PTH, which has yet 
to be fully characterized to determine clinical utility and/or confounding effects 
on present-day assays. The accurate examination of known PTH variants and the 
simultaneous evaluation of other possible variants requires a degree of analytical 
freedom that universally escapes conventional assays. Here we describe mass 
    100 
spectrometric immunoassays (MSIA) that, although specifically designed for the 
detection of PTH (1- 84) and PTH (7-84), also facilitate the simultaneous 
discovery and evaluation of further microheterogeneity in PTH.  
EXPERIMENTAL 
APPROACH 
As a starting point for the development of selected reaction monitoring (SRM)-
based assays for PTH, we surveyed the literature to define molecular variants 
already identified. In addition to the well-characterized truncated variants (e.g., 
PTH (1-84) and PTH (7-84), 4 other molecular versions have been reported in the 
literature as present in human biofluids (primarily plasma or serum). Aligning 
these fragments to the sequence of PTH (1-84) produced a variant map revealing 
forms stemming predominantly from N-terminal truncations (Fig. 23A). A 
conserved region (among several variants) was evident between residues 48 to 84. 
This region was suitable for immmunoaffinity targeting to capture ragged N-
terminal variants (e.g., PTH (1-84) and PTH (7-84). We used a full-scan MSIA 
(MALDI-TOF MS) (15, 25, 154-157) akin to the assay reported by Zhang et al. 
(158) to capture these variants and to discover other variants that were 
immunoreactive with the antibody (Fig. 23B). Postcapture digestion of retained 
PTH (and variants) created the basis for SRM- MSIA (19, 159-162), for which 
surrogate peptides representative of the different PTH variants were selected for 
analysis (Fig. 23C). 
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REAGENTS 
Goat polyclonal anti-PTH (39-84) antibody was purchased from Immutopics 
International. Recombinant human PTH (rhPTH) was obtained from Bachem. 
Pre-mixed 2-[morpholino]ethanesulfonic acid-buffered saline powder packets 
were from Pierce. Extraction of PTH from plasma was carried out with 
proprietary MSIA pipette tips (MSIA-Tips) from Intrinsic Bioprobes derivatized 
with the PTH antibodies via 1,1’-carbonyldiimidazole chemistry as described 
below. Premade 0.01 mol/L HEPES-buffered saline with 3 mmol/L EDTA and 
0.05% (vol/vol) surfactant P20 (HBS-EP) was purchased from Biacore. Synthetic 
heavy-labeled peptides were obtained from ThermoFisher. All other chemicals 
were obtained from Sigma-Aldrich. 
SAMPLES 
All samples used in this study were acquired under an Institutional Review Board 
approved protocol, and informed consent was obtained from all study participants. 
A total of 24 serum samples, from 12 individuals with a diagnosis of severe renal 
impairment or end stage renal disease (10 males and 2 females; mean age 66.7 
years) and 12 healthy individuals (10 males and 2 females; mean age 65 years) 
were used in the study. Of the patients with renal failure who donated samples, 3 
were Hispanic, 2 were Asian, 2 were African American, and 6 were white. The 
ethnicity information for the healthy sample donors was not available. Calibration 
curves were prepared from pooled human plasma by step-wise, 2-fold serial 
dilution of an initial sample containing rhPTH at a concentration of 1000 ng/L (8 
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steps, range 1000–7.8 ng/L). Samples were frozen at -80 °C until use. 
SAMPLE PREPARATION AND IMMUNOCAPTURE 
MSIA-Tips were prepared by Intrinsic Bioprobes as previously described (17-22). 
Before analysis, samples were thawed to 25 °C in a water bath, and 1 mL of 
serum (or plasma) was diluted with 750 μL HBS-EP buffer to a total analytical 
volume of 1.75 mL. PTH was then extracted with the aid of a Beckman Multimek 
96 pipetting robot by repeatedly (1500 repetitions) drawing and expelling (back 
into the analytical volume) 125-μL aliquots of the analytical volume through the 
antibody-prelinked MSIA-Tip. After extraction, the pipettes were rinsed with 
HBS-EP and H2O (in this order; each rinse = 15 repetitions of 150 μL), after 
which PTH was either immediately eluted for detection with MALDI-TOF MS or 
digested and analyzed with high-resolution liquid chromatography–tandem MS 
(LC-MS/MS) or SRM as described below. 
MALDI-TOF MASS SPECTROMETRY 
Samples were prepared for MALDI-TOF MS by drawing 4 μL of MALDI matrix 
solution [saturated aqueous solution of sinapic acid, in 33% (vol/vol) acetonitrile, 
0.4% (vol/vol) trifluoroacetic acid] into the pipette and depositing it onto a 
MALDI-TOF MS target (136). We performed MALDI-TOF MS using a Bruker 
Ultraflex MALDI-TOF instrument operating in the positive ion, delayed-
extraction mode; reflector engaged with ion source 1 at 25.00 kV, ion source 2 at 
21.90 kV, lens at 9.50 kV, reflector at 26.30 kV, reflector 2 at 13.80, 340 ns 
delayed extraction, deflection signal suppression up to m/z 4000, and 2 GS/s 
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sample rate. We signal averaged 10 000 laser shots for each mass spectrum using 
a laser repetition rate of 100 Hz. Isotopically average spectra were externally 
calibrated with a mixture of bovine insulin ([M+H]+ = 5734.52), cytochrome c 
([M+2H]2+ = 6181.05), ubiquitin ([M+H]+ = 8565.76), and cytochrome c ([M+H]+ 
= 12360.97) (all 4 from Bruker). 
SAMPLE ELUTION AND TRYPSIN DIGESTION 
Bound proteins were eluted from the tips into a 96-well plate (AB-1300, Abgene) 
by pipetting 100 μL of 30% acetonitrile/0.5% formic acid up and down for a total 
of 15 cycles. Samples were lyophilized to dryness and then resuspended in 30 μL 
of 30% n-propanol/100 mmol/L ammonium bicarbonate, pH 8.0, diluted with 100 
μL of 25 mmol/L acetic acid containing 100 ng of trypsin. Samples were allowed 
to digest for 4 h at 37 °C. After digestion, samples were lyophilized and 
resuspended in 30 μL of 3% (vol/vol) acetonitrile/0.2% (vol/ vol) formic 
acid/glucagon/PTH heavy peptides. 
HIGH-RESOLUTION LC-MS/MS 
High-resolution LC-MS/MS analysis was carried out on an LTQ-Orbitrap XL 
mass spectrometer (ThermoFisher Scientific). Samples in 5% (vol/vol) 
acetonitrile/0.1% (vol/vol) formic acid were injected onto a 75-μm x 25-cm fused 
silica capillary column packed with Hypersil Gold C18AQ 5-μm media 
(ThermoFisher Scientific), in a 250 μL/min gradient of 5% acetonitrile/0.1% 
formic acid to 30% acetonitrile/0.1% formic acid over the course of 180 min, with 
a total run length of 240 min and a flow rate of 285 nL/min. The LTQ-Orbitrap 
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was run in a top 5 configuration at 60-K resolution for a full scan, with 
monoisotopic precursor selection enabled, and +1 and unassigned charge state 
rejected. The analysis was carried out with collision induced dissociation and 
higher collision energy dissociation fragmentation modes. 
SRM ASSAYS 
SRM assays were developed on a TSQ Vantage triple-quadrupole mass 
spectrometer, an Accela pump, a CTC PAL Autosampler, and an IonMax Source 
equipped with a high-flow metal needle (ThermoFisher Scientific). A mass 
window of full width at half maximum of 0.7 (unit resolution) was used in the 
SRM assays because immunoenriched samples had a very high signal-to-noise. 
Narrower windows were necessary when the matrix background was significant 
and caused interferences in the SRM channels that re- duced signal-to-noise. 
Reversed-phase separations were carried out on a 1-mm x 100-mm Hypersil Gold 
1.9-μm C18 particle (ThermoFisher Scientific) with a flow rate of 160 μL/min. 
Solvent A was 0.2% formic acid in LC-MS grade water, and solvent B was 0.2% 
formic acid in LC-MS grade acetonitrile (Optima grade reagents, ThermoFisher 
Scientific). Pinpoint software (ThermoFisher Scientific) was used for targeted 
protein quantification. The recently developed software algorithm automated the 
prediction of candidate peptides and the choice of multiple fragment ions for 
SRM assay design, as well as automating peptide identity confirmation and 
quantitative data processing. For the workflow described herein, the intact PTH 
sequence was imported into Pinpoint and digested with trypsin in silico, and then 
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transitions for each peptide were predicted by use of the batch option in the 
software. This initial list of peptides and transitions was tested with recombinant 
PTH digest to determine those peptides and transitions delivering optimal signal. 
After several iterations, a subset of 6 peptides with multiple transitions was 
chosen. Further assays were conducted with this optimized method. Once the 
target peptides were identified, heavy arginine or lysine versions were synthesized 
(ThermoFisher) to be used as internal quantitative standards. Target peptides were 
subsequently identified and quantified by coeluting light- and heavy-labeled 
transitions in the chromatographic separation. Time alignment and relative 
quantification of the transitions was performed with Pinpoint. All samples were 
assayed in triplicate. 
RESULTS AND DISCUSSION 
TOP-DOWN ANALYSIS AND DISCOVERY OF NOVEL VARIANTS 
The approach described herein coupled targeting a common region of PTH by use 
of a polyclonal antibody (raised to the C-terminal end of the protein) with 
subsequent detection by use of MS (either MALDI-TOF MS or SRM). Using a 
top-down approach (MALDI- TOF MS), we discovered novel truncated PTH 
variants in clinical samples (Figure 23). The lower panel of Fig. 23 shows 2 
MSIA (MALDI-TOF MS) spectra representative of those obtained from plasma 
samples of 12 individuals with renal failure and 12 healthy controls.  
 
    106 
Signals corresponding to the previously reported N-terminally truncated variants 
are indicated, as well as additional signals aligning with other novel variants. 
 
 
 
 
 
 
Figure 23: PTH variant map with SRM fragments. (A), N-terminally truncated 
PTH variants identified previously [D’Amour (11 ), Zhang et al. (23 )]. (B), 
Variants added to map during this study by use of full-scan MSIA (MALDI-TOF 
MS) (see Fig. 2). (C), Conserved and truncated tryptic fragments chosen for SRM-
MSIA. Bottom panel: MSIA (MALDI-TOF MS) spectra representative of the 12 
samples from patients with renal failure (blue) and the 12 from healthy controls 
(red). The following species were consistently found at higher frequency relative 
abundance in the renal failure cohort (m/z observed; calculated): PTH (1–84) 
(9426.03; 9425.71), PTH (28–84) (6179.61; 6179.91), PTH (34–84) (5472.91; 
5473.16), PTH (37–84) (5155.71; 5155.77), PTH (38–84) (5051.92; 5051.61), PTH 
(34–77) (4715.98; 4716.26), PTH (37–77) (4397.71; 4398.87), PTH (45–84) 
(4379.65; 4379.82), PTH (38–77) (4285.57; 4285.71) and PTH (48–84) (4136.42; 
4136.60). 
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Notably, a conserved cleavage site (residue 77) was observed in several of these 
new variants (Figure 23B). With the exception of PTH (7-84), the variants 
depicted in Figure 23, A and B, were detected in the majority of clinical samples 
and were not readily evident in the control samples (Table 6). 
 
As demonstrated in the top-down analysis described above, we were able to 
simultaneously extract numerous PTH variants with a single, high-affinity 
polyclonal antibody, and the selection of the epitope was directed by the desired 
assay target (i.e., intact and N-terminal variants). Our primary goal was to 
differentiate between intact PTH (1-84) and N-terminal variant PTH (7-84), while 
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simultaneously identifying any additional N-terminal heterogeneity throughout 
the molecule. The results of these top-down experiments allowed the development 
of an initial standard profile for PTH. Clearly, this profile is not finite, and may be 
expanded to include additional variants found through literature search and/or 
complementary full-length studies. However, this standard profile provided an 
initial determination of target sequences for developing specific SRM assays. 
SELECTION OF TRANSITIONS FOR SRM 
During LC-MS/MS analysis, multiple charge states and fragmentation ions are 
generated from each fragment, resulting in upward of 1000 different 
precursor/product transitions possible for PTH digested with trypsin. Owing to 
time and cost restrictions, the empirical investigation of each transition was not 
efficient; therefore, a workflow incorporating predictive algorithms with iterative 
optimization was used to predict the optimal transitions for routine monitoring of 
tryptic fragments. The workflow we developed using Pinpoint for development of 
multiplexed SRM assays is shown in Figure 24. The strategy facilitated the 
translation of empirically obtained peptide intensity and fragmentation behavior 
from high-resolution LC-MS/MS to triple-quadrupole MS SRM assays. Inherent 
to the success of the workflow was the similarity of peptide ion frag- mentation 
behavior in trap and triple-quadrupole instruments (163). Empirical data from 
such LC-MS/MS experiments were used in conjunction with computational 
methods (e.g., in silico tryptic digestions and prediction of SRM transitions) to 
enhance the design of effective SRM assays for selected PTH peptides. 
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Using this approach, we generated an initial list of transitions (data not 
shown) queried empirically to produce an LC-MS/MS profile initially based on 4 
tryptic peptides that collectively spanned >50% of the full-length PTH sequence 
(45 of 84 amino acids). Of these, SVSEIQLMHNLGK [amino acid (aa)1–13] was 
monitored to represent PTH species with an intact N-terminus—i.e., PTH (1-84). 
Other tryptic peptides, HLNSMER (aa14-20), LDQVHN FVALGAPLAPR 
(aa28-44), and ADVNVLTK (aa73-80) were included for monitoring across the 
PTH sequence. In addition, transitions for 2 truncated tryptic peptides, 
LMHNLGK (aa7–13) and FVALGAPLAPR (aa34 – 44), were added to the 
Figure 24: Pinpoint workflow for development of multiplexed SRM 
assays.Q, quadrupole; mSRM, multiple SRM; Int., intensity; I.S., internal 
standard; Conc, concentration. Time measurements are in minutes (min). 
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profile to monitor for truncated variants PTH (7-84) and PTH (34-84), 
respectively. In summary, 32 SRM transitions tuned to these 6 peptides were used 
to monitor intact and variant forms of PTH (Fig. 23C presents the intact peptide 
identities). 
GENERATION OF STANDARD CURVES AND LIMITS OF DETECTION 
AND QUANTIFICATION 
We used rhPTH spiked into stock human blood plasma to create calibration 
curves for all target tryptic peptides through serial dilution. As illustrated in 
Figure 25 for peptides LQDVHNFVALGAPLAPR (aa28-44) and 
SVSEIQLMHNLGK (aa1-13) respectively, SRM transitions for the 4 wild-type 
tryptic fragments exhibited linear responses (R2 = 0.90 – 0.99) relative to rhPTH 
concentration, with limits of detection for intact PTH of 8 ng/L and limits of 
quantification for these peptides calculated at 31 and 16 ng/L, respectively. 
Standard error of analysis for all triplicate measurements in the curves ranged 
from 3% to 12% for all peptides with <5% chromatographic drift between 
replicates. In addition, all experimental peptide measurements were calculated 
relative to heavy-labeled internal standards, and the CVs of integrated areas under 
the curve for 54 separate measurements (for each heavy peptide) ranged from 5% 
to 9%. Monitoring of variant SRM transitions showed no inflections relative to 
rhPTH concentration, as may be expected owing to the absence of truncated 
variants in the stock rhPTH. 
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EVALUATION OF CLINICAL SAMPLES 
Initial SRM data were acquired from replicate plasma samples. Chromatograms 
for peptides SVSEIQLM HNLGK (aa1–13), LQDVHNFVALGAPLAPR (aa28 – 
44), and LMHNLGK (aa7–13) are shown in Figure 26. Peak integration area and 
individual fragment transitions for both light and heavy peptides are illustrated. 
The light and heavy peptides coeluted precisely in all samples. Further SRM 
experiments were then carried out on the cohort of renal failure (n = 12) and  
Figure 25: SRM calibration curves for PTH peptides. A) Peptide 
LQDVHNFVALGAPL-APR aa28–44. B) Peptide SVSEIQLMHNLGK aa1–
13. 
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Figure 26: Chromatograms for peptides SVSEIQLM HNLGK (aa1–13), LQDVHNFVALGAPLAPR 
(aa28 – 44), and LMHNLGK (aa7–13) for A, B, and C, respectively. Peak integration area and individual 
fragment transitions for both light and heavy peptides are illustrated. 
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normal (n = 12) clinical samples. Based on the MALDI-TOF MS data presented 
in Figure 23, bottom panel, and Table 6, the most prominent PTH variant in the 
renal failure samples was PTH (34-84). To quantify this observation with SRM, 
we interrogated all samples to determine the expression ratios of renal failure to 
normal for the various target peptides, including FVALGAPLAPR (aa34-84), 
which should be specific to the 34-84 variant. Chromatographic data from single 
renal failure samples for peptides FVALGAPLAPR (aa34-84) and SVSEIQLM 
HNLGK (aa1-13) are shown in Figure 27.  
 
Figure 27. Pinpoint SRM data from clinical samples of normal and renal 
failure patients. Chromatographic data illustrate peak integration area and 
individual fragment transitions for peptides from single renal failure samples. (A), 
Semitryptic peptide FVALGAPLAPR (aa34–44), specific to the 34–84 variant 
(see Fig. 1). (B), Tryptic peptide SVSEIQLMHNLGK (aa1–13). 
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The peak integration area and individual coeluting fragment transitions for each 
peptide are illustrated. Similar chromatograms were obtained for peptides 
LQDVH NFVALGAPLAPR (aa28-44), HLNSMER (aa14-20), and ADVNVLTK 
(aa73-80) (data not shown). The sample variances and expression ratios of renal 
failure to normal clinical samples for each peptide are shown in Figure 28. The 
expression ratios for the peptides ranged from 4.4 for FVALGAPLAPR (aa34-84) 
to 12.3 for SVSEIQLMHNLGK (aa1-13).  
 
 
Figure 28. SRM quantitative ratios and sample variances of PTH peptides in 
samples from renal failure patients (Renal) and healthy controls. Ratios refer 
to the average value of the renal cohort divided by the average value of the 
healthy control cohort. 
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We did not detect notable quantities of peptide LMHNLGK (aa 7–13) in these 
samples. Sample variances illustrated in the scatter plots in Fig. 5 demonstrate 
that the renal failure and normal samples groups were clearly segregated by the 5 
target peptides. 
Many current clinical assays are based on the quantification of an analyte 
(protein) bound to an immobilized antibody and detected with another antibody 
labeled with a fluorophore, radioisotope, or reporter enzyme. For proteins of 
clinical interest, these techniques are limited by the ability of the antibodies to 
discriminate microheterogeneity in the target analytes, i.e., different molecular 
species that are very similar in structure. This limitation means that current assays 
do not capture the full information content of a target analyte (and its variants), 
which often results in ambiguities in the exact molecular species under 
investigation. Because upstream causes and downstream effects of disease are 
often due to such structural modifications, these limitations represent significant 
problems during the routine analysis of clinically significant analytes. A solution 
to this problem is to use mass spectrometry to accurately detect, identify, and 
quantify heterogeneous ligands captured by antibodies. 
We developed an SRM-MSIA capable of simultaneously monitoring full-
length PTH and truncated variants with analytical metrics suitable for clinical 
research use. The primary object of our investigations was the design of assays 
able to capture data on 2 of these species — PTH (1-84) (intact) and PTH (7-84) 
(an N-terminal variant). Through judicious choice of antibody, we eliminated 
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potentially confounding data from PTH (1-34)  (because it was not captured and 
did not enter into the analysis). Using a workflow incorporating postcapture 
tryptic digestion, surrogate peptides representative of these 2 species were 
generated and monitored by using SRM. In addition, tryptic fragments spanning 
other regions of PTH were incorporated into the analysis. Relative ion signals for 
these species confirmed that the assay was functional and created the basis for a 
standard PTH profile. This standard profile was expanded to include a peptide 
representative of a novel clinical variant PTH (34-84), clipped at the N-terminus. 
In its present form, 32 SRM transitions are analyzed in a multiplexed assay to 
monitor nonvariant PTH sequences with >50% sequence coverage, as well as the 
2 truncated variants. In further work, a systematic workflow allowed for the 
construction of an expandable variant map that presently contains an additional 8 
molecular forms of PTH, including variants exhibiting conserved C-terminal 
truncations (i.e., truncations at PTH77). These newfound variants can be regarded 
in only 2 ways—as novel molecular forms of potential clinical value, or analytical 
nuisances that stand to confound PTH analysis. In either case, construction of 
assays responsive to such possibilities is critical to achieving the most accurate 
qualitative and quantitative definitions of PTH and its related variants. Given that 
such differentiation is now warranted in clinical research applications, rationally 
designed MSIAs and associated integrated workflows, as presented here, will 
facilitate this goal. 
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Chapter 9 
PERFORMANCE CHARACTERISTICS OF INTACT (I)-PTH ASSAYS 
RELATIVE TO A MASS SPECTROMETRIC IMMUNOASSAY FOR 
PARATHYROID HORMONE 
In the present study, a mass spectrometric immunoassay specific for parathyroid 
hormone is evaluated relative to two Intact (I)-PTH assays: the Roche Cobas 
assay and the Beckman Coulter Access 2 assay. Recent studies have shown 
significant variability among PTH assays, with one study reporting PTH levels 
ranging from 60 – 152%, on average, relative to a third generation PTH assay 
(164, 165). This is of significance due to (I)-PTH assays routine use in the 
management of end stage renal disease. Thus, variability among commercial PTH 
assays could, conceivably, present adverse patient outcomes.  Although much 
work has been done on establishing the variability among conventional 
immunoassays, there exists a need to establish a gold-standard reference method 
that is molecule specific and not immunereactive specific. This may be 
accomplished via the use of a mass spectrometric immunoassay whereby the 
analyte is captured using an antibody (or multiple antibodies) with an epitope 
intelligently selected within the context of a protein’s established circulating 
presentation (which may be determined from mass spectrometric population 
studies population studies (21)), followed by unambiguous mass spectrometric 
detection. Therefore, determining the extent to which (I)-PTH assays report 
parathyroid hormone levels relative to unequivocal mass spectrometric detection 
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of intact N-terminal PTH, the portion of the molecule responsible for exerting the 
classical effects of maintaining calcium homeostasis, may provide a definitive 
reference assay. This would not only aid in determine the relative degree of PTH 
heterogeneity interference within commercial assays, but ensure that commercial 
assays provide adequate levels of performance for the diagnosis and treatment of 
end-stage renal disease. 
 
EXPERIMENTAL 
SAMPLES 
For the Cobas study, a collection of 129 human samples comprised of a mix of 
plasma (K2 EDTA collection tubes) and serum (silicone-coated interior collection 
tubes) samples were collected under an Institutional Review Board approved 
protocol. All samples were collected with informed consent. Samples were 
assayed blind and are assumed to vary in clinical severity. For the Access 2 study, 
eighty-nine serum samples (silicone-coated interior collection tubes) were 
collected under an Institutional Review Board approved protocol. All samples 
were collected with informed consent. Samples were assayed blind and are 
assumed to vary in clinical severity. Samples were frozen at -80 °C until use. 
ASSAYS 
(I)-PTH assays (Cobas assay; Roche Diagnostics, Indianapolis, and Access 2 
assay; Beckman Coulter, Fullerton, CA) were run according to the manufactures 
protocol.  
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The mass spectrometric immunoassay for parathyroid hormone was run in SRM-
mode as previously described (26). 
STATISTICAL ANALYSIS 
Patient data was processed using Microsoft Excel 2007. Linear regression 
analysis was performed between (I)-PTH assays relative to the mass spectrometric 
method.  
 
RESULTS AND DISCUSSION 
ROCHE COBAS PTH ASSAY VS. MSIA FOR PTH 
One hundred and twenty nine human samples were assayed over a period of three 
days. The tryptic/SRM PTH peptides (1-13), (14-20), (28-44), (34-44), and (73-
80) were quantified, as previously described (26). Duplicate samples were run in 
parallel on an automated second-generation PTH assay (i.e. an Intact (I)-PTH 
Assay; the Cobas platform from Roche Diagnostics) (166, 167). The Cobas assay, 
which utilizes electrochemiluminescence detection, incorporates a capture 
antibody specific for the C-terminal portion of the molecule, PTH (38-84), and a 
reporter antibody specific for the N-terminal PTH (1-37) region of the molecule. 
Figure 29A shows a side-by-side comparison of PTH (1-13) quantification 
relative to the Cobas assay. Regression analysis produced and equation of y = 
0.83x - 15.76 with R2 = 0.84. Despite the slope (m = 0.83) and R2 value indicating 
a relatively strong assay correlation, thus supporting the relative efficacy of the 
PTH MSIA, the < 1 slope and negative y-intercept is suggestive that the Cobas 
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assay is likely cross-reacting with N-terminally truncated PTH variants and that 
there is a back-ground level assay interference, hence the assays tendency to 
presumably overestimate intact PTH levels. Figure 29B presents a similar 
analysis but uses quantification of PTH (73-80) as the comparison. Regression 
analysis produced the equation of y = 3.38x + 62.21 with R² = 0.53. The > 1 slope 
and positive y-intercept may be interpreted in the context of PTH presentation in 
serum largely existing as N-terminally truncated forms, and due to the MSIA’s 
ability to distinguish between intact N-terminal PTH (1-13) and the C-terminal 
region of the molecule (73-80) via the use of signature SRM tryptic peptides, the 
assay provides a higher-degree of information content regarding the true 
presentation PTH as it exists in circulation. Table 7 presents sample data from the 
first 10 patients assayed on day 1. Indeed, 10 out of 10 samples report higher PTH 
levels on the Cobas assay relative to quantification of PTH (1-13) via MSIA 
quantification, with signature peptides from the mid to C-terminal region of PTH 
showing substantial elevated levels of PTH degradation. For example, patient #8 
had a PTH (1-13) concentration of 321 pg/mL (Cobas PTH concentration of 372 
pg/mL) and a PTH (73-80) concentrations of 2373 pg/mL. Interestingly, 
quantification of PTH (14-20) is lower than PTH (1-13) in most samples (it might 
be assumed that PTH (14-20) would be at least be equal in concentration, if not 
elevated). This seemingly irregular result might be explained by a few recent 
studies. One study presented data from third generation PTH assays (e.g. 
Scantibodies PTH assay) coupled with HPLC separation of PTH isoforms.  
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Figure 29: Commercial (I)-PTH assays vs PTH MSIA assay. A and B: (I)-PTH 
values for 129 patient samples measured with the commercial cobas (I)-PTH 
assay (x-axis) plotted against PTH 1-13 (A) and PTH 73-80 (B) obtained with the 
PTH MSIA (y-axis). C: (I)-PTH values for 89 (separate cohort) patient samples 
measured with the commercial access (I)-PTH assay (x-axis) plotted against PTH 
1-13 (C) obtained with the PTH MSIA (y-axis). Linear regression analysis was 
performed.  
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This type of separation yielded a novel immunoreactive variant of PTH that was 
slightly more hydrophilic, but as-of-yet, structurally unconfirmed isoform of PTH 
(114, 168). Repeat HPLC separation of this novel PTH isoform coupled with 
second-generation PTH assays with epitopes in the 12-18 and 12-24 region 
resulted in poor immunoreactivity. Conversely, this variant reacts normally in 
second generation assays that have 26-32 epitopes, suggesting some type of 
modification around residues 12-18 (114). Although unconfirmed, residue 17, a 
serine, is hypothesized to exist as a phosphorylated variant. Subsequent PTH 
SRM MSIA studies will be specific for this putative variant as well. SRM 
quantification data representing PTH (1-13), (14-20), (28-44), (34-44), and (73-
80) is not shown. 
BECKMAN ACCESS PTH ASSAY VS. MSIA FOR PTH (AND COBAS 
ASSAY) 
Eighty-nine samples were assayed using both on an electrochemiluminescence 
detection-based Beckman Coulter Access 2 PTH platform (167) and a MSIA for 
PTH (in SRM mode) (26). The Access 2 PTH assay is an automated second-
generation PTH assay (aka an Intact (I)-PTH Assay). Of note, capture and 
reporter antibodies epitopes are proprietary information and thus unknown but are 
assumed to be fairly similar to the Cobas assay. As seen in Figure 29C, a direct 
comparison of quantification of PTH (1-13) to “Intact” PTH levels on the 
Beckman assay yields a linear regression equation of y = 0.3994x - 8.8875 and an 
R² of 0.68. These results indicate the Beckman assay may be significantly over-
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estimating bioactive PTH levels. SRM quantification data representing PTH (1-
13), PTH (14-20), PTH (28-44), PTH (34-44), and PTH (73-80) is not shown. 
Table 8 presents an overview of the two studies within the context of 
bioactive PTH quantification. Due to samples from the Cobas study containing an 
excess of clinical samples with relatively high levels of PTH, all samples with 
PTH > 300pg/mL were removed from this dataset with the intent to provide a 
more balanced side-by-side comparison (nonetheless, the two cohorts are assumed 
to be clinically distinct from on another). For comparison purposes, SRM PTH (1-
13) quantification is considered the reference assay and is presumed to completely 
accurate in representing bioactive intact PTH due to antibody specificity and 
unequivocal, molecule specific, mass spectrometric detection of the intact N-
terminus. The percent detected is equivalent to the average ((I)-PTH / MSIA) 
multiplied by 100. The Cobas and Access 2 assays exhibited large disparities 
relative to the reference assay: 202% and 452%, respectively (statistically 
significant from the SRM PTH [1-13] quantification at p < 0.001 for both assays). 
This is striking when one considers the ramifications in regards to the 
personalized treatment of parathyroid disorders which include administration of 
specific dosage quantities of Vitamin D sterols based upon specific PTH levels 
and whether or not to prescribe a parathyroidectomy (i.e. removal of one or both 
of the parathyroid glands), also determined by circulating PTH levels (169). In 
other words, a patient could conceivably receive an entirely different diagnosis 
and treatment depending entirely upon the specific assay the physician happens to 
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be using (e.g. the Cobas or Access 2). Due to the blind nature of this study 
(sample identify information was not available at time of publication), the large 
discrepancy between the mean of [1-13] MSIA in the Cobas study relative to the 
Access 2 is assumed to be due to disparate clinical cohorts.  
Due the increased presence of C-PTH fragments in certain ailments such as 
with end stage renal disease (e.g. PTH (34-84) (26)), this side-by-side comparison 
of two second-generation PTH platforms with a PTH mass spectrometric 
immunoassay supports the idea that there exists a clinical need for a total PTH 
quantification (intact N-terminal PTH and variants). At the very least, a better 
understanding of the relative degree of PTH variant interference across the 
spectrum of the parathyroid hormone molecule (e.g. PTH (1-13), (14-20), (28-44), 
(34-44), and (73-80)) with regards to commercially available assays is clinically 
beneficial. 
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Chapter 10 
CONCLUSION 
As proteomics hinges on moving into widespread use in clinical diagnostics, there 
is an opportunity at hand. Through targeted proteomics efforts focused on full-
length characterization of human proteins, studies such as those described herein 
have the potential to begin documenting the enigmatic landscape of protein 
diversity across human populations. Beyond the exciting prospects this has in 
supporting the expansion and revision of currently held assumptions in protein 
biology (e.g. parathyroid hormone), the notion of reporting the natural variation of 
protein heterogeneity may have long-term implications for diagnostics. Indeed, 
the RANTES MSIA study presented herein describes nineteen variant forms 
comprised of truncated, glycated, glycosylated, and oxidized RANTES that 
collectively discriminated between healthy, T2D, congestive heart failure, 
myocardial infarction, and various combinations thereof -- in a single multiplexed 
assay (Figures 17-20). This exemplar of variant efficacy towards diagnosis may 
be just the beginning and the prognosis value remains to be seen. 
However, a more pertinent consideration is the implication protein diversity 
has for candidate biomarkers discovered using “peptide fingerprints” (170). As 
candidate biomarkers transition down the “biomarker pipeline” towards 
verification and validation, quantification approaches based on surrogate peptide 
detection modalities (e.g. SRM based-assays) should be thoughtful of protein 
diversity in the context of interference as well as diagnostic usefulness. This holds 
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true for classical markers that have remained relatively accepted since their 
implementation into mainstream diagnostics prior to MALDI and ESI (e.g. insulin 
and C-peptide). Indeed, Duncan et al. cautions that “quantification of any 
modified or potentially modified protein, e.g., oxidized, nitrated, alternatively 
spliced, truncated forms, etc. presents a dilemma. Whether measurement is based 
on an unmodified or modified peptide, no qualitative or quantitative insights into 
any of the other forms are available…Under these circumstances the 
“verification” study may cloud rather than clarify.”(170). As such, next-
generation assays employed to quantify insulin, C-peptide, RANTES, and/or 
parathyroid hormone within the context of diabetes, kidney disease, and related 
comorbidities stand to benefit from the work presented here.  
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